US SEC Filings Daily Market Digest — February 26, 2026

27-02-2026

Amneal Pharmaceuticals, Inc. filed an 8-K on February 27, 2026, disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific quantitative financial metrics, comparisons, positive or negative changes, or other details are provided in the filing information.

27-02-2026

Cigna Group filed an 8-K on February 27, 2026 (AccNo: 0001140361-26-007049, Size: 162 KB) under Item 7.01 for Regulation FD Disclosure. No specific core event, financial metrics, transactions, or quantitative data are disclosed in the provided filing information. All details on impacts, guidance, or scheduled events remain NOT_DISCLOSED.

27-02-2026

AIR Industries Group filed an 8-K on February 27, 2026, disclosing under Item 1.01 entry into a material definitive agreement. Item 9.01 includes financial statements and exhibits. No specific details on the agreement's terms, parties, value, financial impact, or any quantitative metrics are provided.

27-02-2026

Limitless X Holdings Inc. filed a Form 8-K on February 27, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 2.03 the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 provides financial statements and exhibits. No specific details such as transaction value, parties, terms, financial metrics, or impacts are disclosed.

27-02-2026

Datavault AI Inc. filed an 8-K on February 27, 2026 (AccNo: 0001104659-26-020936), reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. No financial metrics, transaction values, guidance changes, or operational details were disclosed. This represents a material negative development with no mentioned positives or offsets.

27-02-2026

Ultra Clean Holdings, Inc. filed a Form 8-K on February 27, 2026, reporting entry into a material definitive agreement under Item 1.01, other events under Item 8.01, and financial statements and exhibits under Item 9.01. No specific details on the agreement, transaction size, events, financial impacts, or quantitative metrics are disclosed. This is a multi-item filing with no period-over-period comparisons, guidance, or named entities beyond the filer provided.

27-02-2026

Verde Resources, Inc. filed a Form 8-K on February 27, 2026, reporting under Item 5.07 the submission of matters to a vote of security holders, likely related to a shareholder meeting. No specific matters, voting results, outcomes, or any quantitative data such as vote percentages, share counts, or financial implications are disclosed in the provided filing information. This appears to be a mandatory, single-item informational disclosure with no evident positive or negative metrics.

27-02-2026

BrightSpring Health Services, Inc. filed an 8-K on February 27, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing announcing financial results with attached exhibits. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing details.

• ·Accession Number: 0001193125-26-078998
• ·File Size: 1 MB

27-02-2026

27-02-2026

Flutter Entertainment plc filed an 8-K on February 27, 2026 (AccNo: 0001193125-26-078977, Size: 139 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This multi-item filing discloses material information publicly to comply with Regulation FD, with exhibits attached, but specific content details are NOT_DISCLOSED. No financial metrics, transactions, or performance data (positive, negative, or flat) are mentioned.

27-02-2026

Escalade Inc filed an 8-K on February 27, 2026, under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative metrics are disclosed in the provided filing information. This multi-item filing provides metadata on the earnings release but lacks detailed financial data for analysis.

27-02-2026

Ginkgo Bioworks Holdings, Inc. filed an 8-K on 2026-02-27 disclosing entry into a Material Definitive Agreement under Item 1.01. The filing also reports Financial Statements and Exhibits under Item 9.01. No specific details on the agreement terms, transaction value, parties involved, financial impacts, or other metrics are disclosed.

27-02-2026

Bain Capital Specialty Finance, Inc. filed an 8-K on February 27, 2026, disclosing information under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, period-over-period comparisons, transaction details, or guidance are provided in the filing summary. This appears to be a multi-item voluntary or mandatory earnings-related disclosure, but quantitative impacts are NOT_DISCLOSED.

27-02-2026

Abony Acquisition Corp. I filed an 8-K on 2026-02-27 disclosing Other Events under Item 8.01 and Financial Statements and Exhibits under Item 9.01. No specific details on merger or acquisition structure, parties, valuation, synergies, or impacts are provided in the filing summary. Sector is not specified, and no quantitative metrics, comparisons, or scheduled events are mentioned.

• ·AccNo: 0001213900-26-021014
• ·Filing size: 422 KB

27-02-2026

Golden Entertainment, Inc. filed a Form 8-K on February 27, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific financial metrics, period-over-period comparisons, or performance indicators (positive, negative, or flat) are disclosed in the provided filing details. This appears to be a standard earnings-related disclosure with no quantified impacts available.

27-02-2026

Matador Resources Co filed an 8-K on 2026-02-27 disclosing entry into a material definitive agreement under Item 1.01, other events under Item 8.01, and financial statements and exhibits under Item 9.01. This is a multi-item filing with no specific details on the agreement, events, or exhibits provided. No quantitative metrics, positive or negative changes, or financial impacts are disclosed.

• ·Filing Accession Number: 0001104659-26-020877
• ·Filing Size: 500 KB
• ·Sector: NOT_DISCLOSED

27-02-2026

FrontView REIT, Inc. filed a Form 8-K on February 27, 2026, disclosing multiple material events under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 3.03 (Material Modifications to Rights of Security Holders), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific transaction values, share counts, or financial metrics disclosed in the provided information. No positive or negative performance metrics are mentioned.

27-02-2026

Sunoco LP filed a Form 8-K on February 27, 2026, reporting under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. This is a multi-item filing indicating voluntary disclosure of material information previously shared selectively with certain parties, with exhibits attached. No specific details, financial metrics, transactions, or performance data are disclosed.

27-02-2026

Goldman Sachs BDC, Inc. filed an 8-K on February 27, 2026 (AccNo: 0001193125-26-078362), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing announcing financial results, but specific revenue, earnings, balance sheet changes, guidance, or period-over-period comparisons are NOT_DISCLOSED. No positive or negative metrics, scheduled events, or transactions detailed in the provided filing information.

27-02-2026

Northwest Natural Holding Co filed an 8-K on February 27, 2026, under Item 2.02 disclosing results of operations and financial condition, and Item 9.01 for financial statements and exhibits. This multi-item filing reports financial results but provides no specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons in the available information. No quantitative metrics, positive or negative changes, or strategic updates are explicitly stated.

27-02-2026

The company filed an 8-K on February 27, 2026, disclosing entry into a new Material Definitive Agreement under Item 1.01 and termination of a prior Material Definitive Agreement under Item 1.02, alongside other events in Item 8.01 and financial statements/exhibits in Item 9.01. No specific details on the nature, parties, terms, or financial impacts of the agreements are disclosed. This appears to be a replacement or amendment of a prior agreement, but without further context, the net impact remains unclear.

27-02-2026

News Corp filed an 8-K on February 27, 2026 (AccNo: 0001564708-26-000043, size 399 KB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). Specific details of the other events or attached exhibits are NOT_DISCLOSED. No financial metrics, transactions, or performance data are mentioned.

27-02-2026

Duolingo, Inc. filed a Form 8-K on 2026-02-27 under Item 2.02 announcing Results of Operations and Financial Condition, with Financial Statements and Exhibits attached under Item 9.01. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing details. This represents a standard earnings-related disclosure.

27-02-2026

VSE Corp filed an 8-K on February 27, 2026, disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events or the content of the financial statements and exhibits are provided in the filing summary. No quantitative metrics, transactions, or forward-looking information are disclosed.

27-02-2026

Graphic Packaging Holding Co filed an 8-K on 2026-02-27 disclosing entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, accompanied by financial statements and exhibits under Item 9.01. This is a multi-item filing with no specific details on transaction terms, size, parties, or financial impacts provided in the available information. No quantitative metrics, positive or negative performance indicators, or period-over-period comparisons are mentioned.

27-02-2026

Xeris Biopharma Holdings, Inc. filed an 8-K on 2026-02-27 reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely involving voluntary disclosure of material nonpublic information and attached exhibits. No specific financial metrics, transactions, events, or quantitative data are disclosed in the provided filing metadata.

27-02-2026

Anteris Technologies Global Corp. filed an 8-K on February 27, 2026 (AccNo: 0001140361-26-007003), reporting under Item 2.02 Results of Operations and Financial Condition, accompanied by Item 9.01 Financial Statements and Exhibits. This constitutes a multi-item voluntary disclosure of financial results. No specific revenue, earnings, balance sheet details, guidance, or quantitative metrics are disclosed in the provided filing information.

27-02-2026

Trimas Corp filed an 8-K on 2026-02-27 disclosing an officer change under Item 5.02, covering potential departures of directors or certain officers, elections or appointments of directors/officers, and compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on positions affected, individuals involved, reasons for change, or any quantitative metrics are disclosed.

27-02-2026

UWM Holdings Corp filed an 8-K on February 27, 2026 (AccNo: 0001783398-26-000018, size 3 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary filing with no specific details on the disclosed information, financial metrics, transactions, or exhibits provided. No quantitative data, period-over-period comparisons, or directional metrics are mentioned.

27-02-2026

Larimar Therapeutics, Inc. filed an 8-K on February 27, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No details on the agreement, transaction value, financial impacts, or quantitative metrics are disclosed in the provided filing summary. No positive or negative metrics, period-over-period comparisons, or strategic context are mentioned.

27-02-2026

Carter's Inc. filed an 8-K on 2026-02-27 under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits). No specific financial metrics, period-over-period comparisons, guidance, or other quantitative details are disclosed in the provided filing information.

27-02-2026

Delek US Holdings, Inc. filed an 8-K on 2026-02-27 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This multi-item voluntary disclosure pertains to financial results. No quantitative metrics, period-over-period comparisons, guidance, or other specific financial details are disclosed.

27-02-2026

Delek Logistics Partners, LP filed an 8-K on 2026-02-27 disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet impacts, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with attached exhibits.

27-02-2026

INTEST CORP filed an 8-K on February 27, 2026 (AccNo: 0001036262-26-000004, Size: 925 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, margins, period-over-period comparisons, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This is an informational earnings-related disclosure with no detailed performance data available.

27-02-2026

Via Transportation, Inc. filed a Form 8-K on 2026-02-27 under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or quantitative metrics were disclosed in the provided filing information. Sector was not specified.

27-02-2026

NATURAL RESOURCE PARTNERS LP filed an 8-K on 2026-02-27 disclosing under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period metrics are mentioned. This is a standard earnings-related disclosure with no quantified financial impacts provided.

27-02-2026

ANI Pharmaceuticals Inc filed an 8-K on February 27, 2026 (AccNo: 0001023024-26-000013), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics were explicitly stated in the provided filing details. This is a standard disclosure for financial results with no indicated positive or negative performance variations.

27-02-2026

Fulgent Genetics, Inc. filed a Form 8-K on February 27, 2026 (AccNo: 0001193125-26-079152), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results, but specific revenue, earnings, balance sheet details, guidance, or performance metrics are NOT_DISCLOSED. No positive, negative, or flat metrics, period-over-period comparisons, or other quantitative data are provided in the filing summary.

27-02-2026

1stdibs.com, Inc. filed an 8-K on February 27, 2026, reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period comparisons were disclosed in the provided filing information. This is an informational earnings-related disclosure without quantified metrics.

27-02-2026

TXNM Energy Inc filed an 8-K on February 27, 2026, reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed financial data available.

27-02-2026

NIQ Global Intelligence plc filed a Form 8-K on 2026-02-27 under Item 2.02 announcing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, margins, guidance, period-over-period changes, or other quantitative metrics are disclosed in the filing summary. This is a standard voluntary earnings-related disclosure without detailed financial data provided.

27-02-2026

Smurfit Westrock plc filed an 8-K on 2026-02-27 disclosing an Item 5.02 event related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Specific details including key positions affected, individuals involved, reasons for change, appointment or resignation type, timing, or compensatory terms are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or other material changes are mentioned.

27-02-2026

Nuveen Municipal Value Fund Inc filed a Form 8-K on February 27, 2026, under Item 8.01 Other Events. No specific details regarding the core event, transaction, financial metrics, positive or negative changes, or other quantitative data are disclosed in the filing summary provided. This appears to be a single-item voluntary or mandatory disclosure of a material event not covered by other Items, but content is limited.

27-02-2026

Johnson Outdoors Inc filed an 8-K on February 27, 2026, under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing involving voluntary disclosure of potentially material information via Regulation FD, with exhibits attached. No specific financial metrics, transactions, or quantitative data are disclosed in the provided filing details.

27-02-2026

Nuveen AMT-Free Municipal Value Fund filed a Form 8-K on February 27, 2026, reporting solely under Item 8.01 Other Events. No specific details regarding the nature of the other events, financial metrics, transactions, or impacts are disclosed in the provided filing information. This appears to be a single-item, voluntary disclosure with no quantitative data available.

27-02-2026

Accelerant Holdings filed an 8-K on 2026-02-27 disclosing Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), indicating a financial results announcement. No specific revenue, earnings, guidance, or other quantitative metrics are mentioned in the provided filing details. This is a multi-item filing typical for earnings releases under Regulation FD.

27-02-2026

Roman DBDR Acquisition Corp. II filed an 8-K on 2026-02-27 disclosing entry into a material definitive agreement under Item 1.01, likely related to a merger or acquisition event. The filing also includes Regulation FD Disclosure (Item 7.01), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). No specific deal terms, financial metrics, parties involved, or quantitative details are disclosed.

27-02-2026

Zoomcar Holdings, Inc. filed a Form 8-K on February 27, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the content of the Regulation FD disclosure or the nature of the exhibits provided. No financial metrics, transactions, or performance data are disclosed in the filing summary.

27-02-2026

Healthpeak Properties, Inc. filed an 8-K on February 27, 2026, reporting under Item 7.01 Regulation FD Disclosure. No financial metrics, transactions, or other specific events are detailed in the provided filing information. No positive or negative performance indicators are mentioned.

27-02-2026

Treace Medical Concepts, Inc. filed an 8-K on February 27, 2026, reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a standard earnings-related disclosure. No specific quantitative financial metrics, period-over-period comparisons, guidance, or other numerical data are disclosed in the provided filing details.

27-02-2026

Alpha Metallurgical Resources, Inc. filed an 8-K on February 27, 2026, under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely involving voluntary disclosure of material non-public information with attached exhibits such as press releases or presentations. No specific financial metrics, transaction details, guidance, or quantitative data are disclosed in the filing summary.

27-02-2026

National CineMedia, Inc. filed an 8-K on February 27, 2026, under Item 2.02 disclosing results of operations and financial condition. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period metrics are mentioned in the provided filing information. Detailed financial impacts remain NOT_DISCLOSED.

27-02-2026

TechTarget, Inc. filed an 8-K on February 27, 2026, under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. The filing also includes Item 7.01 for Regulation FD disclosure and Item 9.01 for financial statements and exhibits. Specific details including key positions affected, names, appointment or resignation status, reasons, timing, and any quantitative data are NOT_DISCLOSED.

27-02-2026

Alight, Inc. filed an 8-K on February 27, 2026 (AccNo: 0001193125-26-079261), disclosing an event under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Specific details including the key position affected, individual names, appointment or resignation status, reasons for change, and any compensatory arrangements are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or market impacts are mentioned.

27-02-2026

Sunstone Hotel Investors, Inc. filed an 8-K on February 27, 2026, under Item 2.02 announcing Results of Operations and Financial Condition, with Item 9.01 providing Financial Statements and Exhibits. No specific financial metrics, period-over-period comparisons, or quantitative details are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed performance data available.

27-02-2026

MBX Biosciences, Inc. filed an 8-K on February 27, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 5.02 departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 discloses financial statements and exhibits. No specific details, numerical values, transaction sizes, personnel names, or financial impacts are provided in the filing summary.

27-02-2026

United States Brent Oil Fund, LP filed an 8-K on February 27, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits). No specific financial metrics, transactions, events, positive developments, negative changes, or flat performance indicators are disclosed in the provided filing information. Details of the Regulation FD disclosure and any attached exhibits are NOT_DISCLOSED.

27-02-2026

ALX Oncology Holdings Inc filed an 8-K on February 27, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), disclosing financial results. No specific revenue, earnings, balance sheet metrics, period-over-period comparisons, guidance, or other quantitative details were provided in the filing summary. This is an informational earnings-related disclosure with no directional financial impacts detailed.

27-02-2026

BlackRock TCP Capital Corp. filed an 8-K on February 27, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing for financial results disclosure. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period metrics are disclosed.

27-02-2026

United States 12 Month Natural Gas Fund, LP filed an 8-K on February 27, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific events, transactions, financial metrics, positive or negative changes, or quantitative data are disclosed in the provided filing information. This appears to be a voluntary disclosure of material information with attached exhibits.

27-02-2026

United States Gasoline Fund, LP filed a Form 8-K on February 27, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details, financial metrics, transactions, or events are disclosed in the provided filing summary. Critical content from the disclosure and exhibits is NOT_DISCLOSED.

27-02-2026

United States 12 Month Oil Fund, LP filed an 8-K on February 27, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific details, financial metrics, transactions, or events are disclosed in the provided filing summary. This appears to be a voluntary informational filing with exhibits attached.

27-02-2026

United States Natural Gas Fund, LP filed an 8-K on February 27, 2026, under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details, financial metrics, transactions, or events are disclosed in the provided filing summary. This appears to be a voluntary informational filing with exhibits attached.

27-02-2026

United States Oil Fund, LP filed an 8-K on February 27, 2026 (AccNo: 0001104659-26-021015, Size: 209 KB) reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transactions, period-over-period comparisons, or other quantitative data are disclosed in the filing metadata. No positive or negative performance indicators are mentioned.

27-02-2026

Calumet, Inc. /DE filed an 8-K on 2026-02-27 disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a standard financial results announcement, but specific revenue, earnings, guidance, or period-over-period comparisons are NOT_DISCLOSED in the provided filing details. No positive or negative metrics, transaction values, or operational changes were detailed.

27-02-2026

Globalstar, Inc. filed an 8-K on February 27, 2026, under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, balance sheet details, period-over-period comparisons, or guidance changes were disclosed in the provided filing information. No positive, negative, or flat metrics were mentioned.

27-02-2026

KORE Group Holdings, Inc. filed an 8-K on February 27, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 8.01 other events, and under Item 9.01 financial statements and exhibits. No specific details on the nature of the agreement, events, transaction value, financial metrics, or impacts are disclosed in the provided filing summary. All quantitative data, parties involved, and outcomes remain NOT_DISCLOSED.

27-02-2026

GLOBAL PARTNERS LP filed an 8-K on February 27, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing announcing financial results, but specific revenue, earnings, guidance, or period-over-period comparisons are NOT_DISCLOSED in the provided filing details. No positive or negative metrics are explicitly stated.

27-02-2026

United States Commodity Index Funds Trust filed an 8-K on February 27, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific events, transactions, financial metrics, or quantitative data are detailed in the filing summary provided. This appears to be a multi-item voluntary disclosure with attached exhibits.

27-02-2026

Criteo S.A. filed an 8-K on February 27, 2026, reporting under Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses shareholder vote matters and additional events, with exhibits attached, but no specific vote outcomes, event details, financial metrics, or quantitative data are provided in the filing summary. No positive or negative performance metrics reported.

27-02-2026

TransMedics Group, Inc. filed an 8-K on February 27, 2026 (AccNo: 0001193125-26-079392), reporting under Item 2.02 Results of Operations and Financial Condition, and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, revenue, earnings, guidance, or period-over-period comparisons are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with attached exhibits.

27-02-2026

Enzon Pharmaceuticals, Inc. filed a Form 8-K on 2026-02-27 reporting entry into a material definitive agreement under Item 1.01 (potential strategic positive) but also material modifications to rights of security holders under Item 3.03 (potential negative for shareholders), alongside Regulation FD disclosure (Item 7.01) and financial statements/exhibits (Item 9.01). This is a multi-item filing with no specific transaction details, dollar values, or financial metrics disclosed. No positive or negative quantitative changes are mentioned.

27-02-2026

Amazon.com Inc filed an 8-K on February 27, 2026, disclosing under Item 1.01 entry into a Material Definitive Agreement, Item 7.01 Regulation FD Disclosure, Item 8.01 Other Events, and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with the core event being a material definitive agreement, though specific details, transaction value, parties, and impacts are NOT_DISCLOSED. No financial metrics, guidance changes, or quantitative impacts are provided in the filing summary.

27-02-2026

DUOS Technologies Group, Inc. filed an 8-K on February 27, 2026, under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 8.01 covers other events and Item 9.01 lists financial statements and exhibits. No specific details on positions affected, names, reasons for changes, financial metrics, or performance impacts are disclosed.

27-02-2026

Equinix Inc filed an 8-K on February 27, 2026, disclosing under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the content of the Regulation FD disclosure or the nature of the exhibits are provided. This appears to be a voluntary informational filing with no quantitative metrics, events, or financial impacts mentioned.

27-02-2026

SIRIUS XM HOLDINGS INC. filed an 8-K on 2026-02-27 under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details on the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information. Filing size is 239 KB with AccNo: 0001104659-26-021044.

27-02-2026

LCI Industries filed a Form 8-K on February 27, 2026 (AccNo: 0000763744-26-000014, Size: 705 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the content of the exhibits are disclosed in the filing summary. This appears to be a multi-item voluntary disclosure with attached exhibits.

27-02-2026

CG Oncology, Inc. filed a Form 8-K on February 27, 2026 (AccNo: 0001193125-26-079452), disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. This is a standard voluntary earnings-related disclosure with no specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons provided in the filing description. No quantitative metrics or directional performance indicators (positive, negative, or flat) are available.

27-02-2026

Arbor Realty Trust Inc filed an 8-K on February 27, 2026, reporting Results of Operations and Financial Condition under Item 2.02 and providing Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period metrics are disclosed in the provided filing information.

27-02-2026

Assured Guaranty Ltd filed an 8-K on February 27, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, revenue, earnings, period-over-period changes, guidance, or quantitative data are disclosed in the provided filing information. This appears to be a standard voluntary earnings-related disclosure without detailed performance indicators.

27-02-2026

reAlpha Tech Corp. filed an 8-K on 2026-02-27 disclosing a Notice of Delisting or Failure to Satisfy a Continued Listing Rule under Item 3.01, alongside Departure of Directors or Certain Officers under Item 5.02, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. This multi-item filing signals a major negative development with delisting, which typically impairs liquidity and investor access, compounded by potential leadership changes. No quantitative financial metrics, transaction values, or period-over-period comparisons are disclosed.

27-02-2026

Nucor Corp filed an 8-K on February 27, 2026, under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 includes financial statements and exhibits. No specific details on affected positions, individuals, reasons for change, or any quantitative metrics are disclosed.

27-02-2026

Albertsons Companies, Inc. filed an 8-K on 2026-02-27 disclosing officer changes under Item 5.02, which covers departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, individuals involved, reasons for changes, or quantitative data are disclosed.

27-02-2026

FG Nexus Inc. filed an 8-K on February 27, 2026, disclosing material modifications to rights of security holders under Item 3.03 and amendments to articles of incorporation or bylaws (or change in fiscal year) under Item 5.03. Item 9.01 references financial statements and exhibits. No specific details, financial impacts, or quantitative metrics on these changes are disclosed in the provided information.

27-02-2026

Acrivon Therapeutics, Inc. filed an 8-K on 2026-02-27 under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the content of the Regulation FD disclosure or the nature of the exhibits are disclosed in the filing summary. This appears to be a multi-item informational filing with no quantified financial metrics or events provided.

27-02-2026

Dynex Capital Inc filed an 8-K on February 27, 2026 (AccNo: 0001104659-26-021080), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), alongside Regulation FD Disclosure (Item 7.01) and Financial Statements and Exhibits (Item 9.01). No specific details on the affected position, individual names, appointment/resignation status, reasons, or timing are disclosed. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

• ·Event date: February 27, 2026
• ·Filing size: 264 KB
• ·Sector: NOT_DISCLOSED

27-02-2026

Elauwit Connection, Inc. filed a Form 8-K on February 27, 2026, under Item 4.02 announcing non-reliance on previously issued financial statements or a related audit report or completed interim review, which signals potential material accounting issues or errors. The filing also includes Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No quantitative financial metrics, transaction details, or scheduled events are disclosed.

27-02-2026

Inmune Bio, Inc. filed an 8-K on February 27, 2026, under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details, financial metrics, transactions, or performance data (positive, negative, or flat) were explicitly stated in the filing summary provided. The filing size of 18 MB suggests potentially significant attached exhibits, but content is NOT_DISCLOSED.

27-02-2026

Avidity Biosciences, Inc. filed an 8-K on February 27, 2026, disclosing the termination of a material definitive agreement (Item 1.02), completion of an acquisition or disposition of assets (Item 2.01), notice of delisting or failure to satisfy listing standards (Item 3.01), material modifications to rights of security holders (Item 3.03), changes in control of the registrant (Item 5.01), departures/elections of directors/officers and compensatory arrangements (Item 5.02), and amendments to articles of incorporation or bylaws (Item 5.03). These items collectively indicate a completed significant corporate transaction involving change of control and delisting, with no financial metrics, deal values, or performance comparisons provided. Item 9.01 references financial statements and exhibits, but specifics are NOT_DISCLOSED.

27-02-2026

Envoy Medical, Inc. filed an 8-K on 2026-02-27 disclosing under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, including transfer of listing. Item 8.01 reports other events, and Item 9.01 includes financial statements and exhibits. No financial metrics, transaction values, or period-over-period comparisons are disclosed.

• ·Multi-item 8-K filing (Items 3.01, 8.01, 9.01)
• ·Filed on 2026-02-27 with AccNo: 0001213900-26-021116

27-02-2026

International Endeavors Corp filed an 8-K on 2026-02-27 under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the Regulation FD disclosure, financial statements, or exhibits are provided. No quantitative metrics, events, or impacts are disclosed.

27-02-2026

NATIONAL HEALTHCARE CORP filed an 8-K on February 27, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, margins, period-over-period comparisons, guidance, or other quantitative financial metrics were explicitly stated in the provided filing details. This informational disclosure provides access to full financial statements without summarized performance highlights.

27-02-2026

Ohio Valley Banc Corp filed an 8-K on February 27, 2026 (AccNo: 0000894671-26-000021, Size: 149 KB), disclosing an officer change under Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Specific details including the key position affected, individuals involved, appointment or resignation status, reasons for change, and any governance or financial impacts are NOT_DISCLOSED. No quantitative metrics, scheduled events, or other financial data are mentioned in the provided filing information.

27-02-2026

Alaska Silver Corp. filed a Form 8-K on February 27, 2026 (AccNo: 0001062993-26-001190, Size: 246 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing likely involving voluntary disclosure of material non-public information with attached exhibits. No specific financial metrics, transactions, events, or quantitative data are disclosed in the provided filing summary.

• ·AccNo: 0001062993-26-001190
• ·File Size: 246 KB

27-02-2026

MGE Energy Inc filed an 8-K on February 27, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific core events, transactions, financial metrics, or period-over-period comparisons are disclosed in the filing summary. Critical details such as dollar values, guidance, or scheduled events are not provided.

27-02-2026

Starwood Real Estate Income Trust, Inc. filed a Form 8-K on February 27, 2026, reporting under Item 8.01 Other Events. No specific details regarding the core event, financial impacts, transaction values, or quantitative metrics are disclosed in the filing metadata provided. No positive or negative performance metrics, period-over-period changes, or scheduled events are mentioned.

27-02-2026

GREENWAY TECHNOLOGIES, INC. & SUBSIDIARIES filed an 8-K on February 27, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, or any quantitative data are disclosed. No positive or negative metrics are mentioned.

27-02-2026

Golkor Inc. filed an 8-K on February 27, 2026, disclosing changes in its certifying accountant under Item 4.01. Item 9.01 reports financial statements and exhibits. No additional details on the nature of the change, reasons, new auditor, financial impacts, or quantitative metrics are provided.

27-02-2026

DEERE & CO filed an 8-K on February 27, 2026, specifically under Item 5.07, reporting the submission of matters to a vote of security holders. This disclosure pertains to the results of a shareholder vote, typically from an annual or special meeting, but no specific proposals, vote tallies, or outcomes are detailed in the provided filing summary. No financial metrics, changes, or other quantitative data are mentioned.

27-02-2026

DarkPulse, Inc. filed an 8-K on February 27, 2026, reporting under Item 5.03 amendments to its Articles of Incorporation or Bylaws, or a change in fiscal year. Item 9.01 discloses financial statements and exhibits. No specific details, quantitative impacts, positive or negative metrics, or further context are provided in the filing summary.

27-02-2026

BancFirst Corp (/OK/) filed an 8-K on 2026-02-27 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and Regulation FD Disclosure under Item 7.01. Specific details including the key position affected, whether it is an appointment or resignation, internal/external status, reason, and timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

27-02-2026

STRATS SM TRUST FOR WAL-MART STORES, INC. SECURITIES, SERIES 2005-4 filed an 8-K on February 27, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial metrics, or exhibits are disclosed in the provided filing information.

27-02-2026

STRATS(SM) TRUST FOR DOMINION RESOURCES, INC. SECURITIES, SERIES 2005-6 filed an 8-K on February 27, 2026, under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details on the other events, financial statements, or exhibits are provided in the filing summary. This appears to be an informational disclosure with no quantified financial metrics, transactions, or impacts mentioned.

27-02-2026

Braemar Hotels & Resorts Inc. filed a Form 8-K on February 27, 2026, under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction details, positive or negative changes, or other quantitative data are disclosed in the provided filing summary. This is a multi-item voluntary filing focused on Reg FD disclosure with attached exhibits.

27-02-2026

Clearfield, Inc. filed an 8-K on February 27, 2026, reporting Item 5.07: Submission of Matters to a Vote of Security Holders. No specific proposals, voting results, or outcomes are disclosed in the provided filing information. This is a single-item informational filing with no financial metrics or quantitative data mentioned.

27-02-2026

UFP Technologies Inc filed a Form 8-K on February 27, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. This multi-item filing discloses material nonpublic information voluntarily and attaches relevant exhibits. No financial metrics, transactions, or operational details are provided.

27-02-2026

CaliberCos Inc. filed an 8-K on February 27, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event, transaction details, financial metrics, positive or negative changes, or quantitative data is explicitly stated or available in the filing summary. This appears to be a voluntary informational disclosure with attached exhibits, but content details are NOT_DISCLOSED.

27-02-2026

Presurance Holdings, Inc. closed its Rights Offering on February 27, 2026, issuing 4,284,640 shares of common stock upon exercise of subscription rights at $1.00 per share and an additional 9,715,360 shares to Clarkston Companies, Inc. under the backstop commitment. The company received $14M in gross proceeds, which are being used to redeem its Series B Preferred Stock including all accrued dividends, and for general corporate purposes. Unexercised rights expired on February 24, 2026, with no negative impacts reported.

• ·Backstop Agreement dated February 3, 2026
• ·Previous 8-K filed January 28, 2026
• ·S-1 registration (File No. 333-292735) effective February 6, 2026
• ·Subscription deadline: 5:00 p.m. ET on February 24, 2026

27-02-2026

Where Food Comes From, Inc. reported full-year 2025 total revenue of $24.9M, down 3.3% YoY from $25.7M, with verification services at $20.1M (-2.2%) and product sales at $3.6M (-5.0%); net income fell 27.5% to $1.5M from $2.1M. Q4 revenue declined 9.3% to $6.0M from $6.7M, swinging to a $0.2M net loss from $1.0M income. Positively, cash and equivalents rose 59% to $3.2M, the company repurchased 183,016 shares, and launched RaiseWell Certified adopted by Whole Foods amid non-beef certification growth.

• ·Gross profit full year 2025: $9.5M vs $10.6M in 2024 (decline 10.0%)
• ·SG&A expense full year: $8.3M vs $8.4M (slight decline)
• ·Q4 SG&A: increased to $2.2M from $2.0M
• ·Supports more than 17,500 farmers, ranchers, vineyards, wineries, processors, retailers, distributors, trade associations, consumer brands and restaurants
• ·Conference call replay available through March 5, 2026

27-02-2026

On February 25, 2026, Myrna M. Soto informed the Board of Directors of Popular, Inc. that she will not stand for re-election upon the expiration of her current term at the 2026 Annual Meeting of Shareholders, scheduled for May 8, 2026. Her decision to retire does not result from any disagreement with the Corporation on operations, policies, or practices. In connection with her retirement, the Board will reduce its size from twelve to eleven directors, effective at the Annual Meeting.

• ·Event reported on February 25, 2026; filing dated February 27, 2026.
• ·Principal executive offices: 209 Muñoz Rivera Avenue, Hato Rey, Puerto Rico 00918.

27-02-2026

Netflix, Inc. announced the termination of its Amended and Restated Agreement and Plan of Merger with Warner Bros. Discovery, Inc. (WBD) on February 27, 2026, following WBD's acceptance of a superior proposal from Paramount Skydance Corporation (PSKY), ending Netflix's planned acquisition of WBD's Streaming & Studios businesses. Netflix received a $2.8B termination fee paid by PSKY on behalf of WBD, providing a financial offset to the lost deal. Related financing commitments, including bridge debt, incremental commitments, revolving credit facility, and delayed draw term loan, were automatically terminated.

• ·Merger Agreement originally amended on January 19, 2026; termination notices exchanged February 26, 2026.
• ·Related financing: Debt Commitment Letter (Dec 4, 2025), Incremental Commitments Agreement (Jan 19, 2026), 2025 RCF (Dec 19, 2025), DDTL Credit Agreement (Dec 19, 2025) all terminated.

27-02-2026

On February 27, 2026, Ameren Missouri, a subsidiary of Ameren Corporation, sold $450 million principal amount of 4.80% First Mortgage Bonds due 2036 and $450 million principal amount of 5.55% First Mortgage Bonds due 2056, receiving aggregate net offering proceeds of approximately $891.1 million before expenses. The bonds were offered pursuant to a Registration Statement on Form S-3 (effective October 13, 2023) and a Prospectus Supplement dated February 23, 2026. This filing includes related exhibits such as the Underwriting Agreement and Supplemental Indenture dated February 1, 2026.

• ·Underwriting Agreement dated February 23, 2026, with representatives Barclays Capital Inc., BofA Securities, Inc., Mizuho Securities USA LLC, MUFG Securities Americas Inc., and Wells Fargo Securities, LLC.
• ·Supplemental Indenture dated February 1, 2026, between Ameren Missouri and The Bank of New York Mellon.
• ·Registration Statement on Form S-3 (File No. 333-274977-02) effective October 13, 2023.

27-02-2026

United States Antimony Corporation (UAMY) reported record revenues and gross profit for Q3 and nine months ended September 30, 2025, alongside key milestones like a $245M sole-source DLA contract, $106.7M U.S. industrial agreement, Madero smelter restart, and Montana mine operations start, boosting market cap from $192M (Jan 1, 2025) to $1.206B (Feb 6, 2026). Zeolite tons sold grew 9% in FY2024 and through Q3 2025 with 98.4% runtime efficiency, while antimony prices surged to $18.94/lb avg in 2024 but declined to $11.79/lb as of Feb 5, 2026. Cash balance remains strong at $90-92M supporting expansions including Thompson Falls smelter to 300 tons/month.

• ·International ore shipments: Chad (400MT initial Nov 2025, >100MT/month ongoing, 60%+ Sb); Peru (47 tons 2025); Australia (160 tons processed, 55 tons rerouted); Bolivia (10MT March 2026 ramp to 150MT/month).
• ·Smelter capacities: Madero 200 tons/month (7 tons/day); Thompson Falls expanding to 300 tons/month (11 tons/day).
• ·Alaska mining permits approved Sep 5, 2025; exploration to begin May 2026.
• ·China/Russia control >60% global antimony ore.
• ·JV with Americas Gold and Silver: 49% USAC ownership for Idaho hydromet plant.

27-02-2026

Healthcare Realty Trust reported robust 2025 performance with Normalized FFO of $1.61 per share (+3% YoY), same-store cash NOI growth of 4.8% driven by 103 bps occupancy increase to 92.1% and 3.1% cash leasing spreads, and completion of ~$1.2B asset sales at 6.7% cap rate. Net debt to Adj. EBITDA improved to 5.4x (down 0.7x YoY) with $1.4B liquidity, while executing Healthcare Realty 2.0 strategic plan including $50M share repurchases and portfolio optimization exiting non-core markets. However, the company right-sized its dividend to $0.24 quarterly (5.2% yield) to save ~$100M annually in cash flow, and SS NOI growth of 4.8% was ahead but within guided range.

• ·93% of portfolio on/adjacent and affiliated to health systems
• ·~5 years WALTR
• ·2026 Guidance: NFFO $1.58–$1.64; SS Cash NOI 3.50%–4.50%
• ·Fixed rate debt 98% at weighted avg. 3.2% interest
• ·Total debt to total assets 36%
• ·Disposition portfolio had 79% occupancy vs current 92%; 1% NOI growth vs current 3.4%; 25% in key markets vs current 74%

27-02-2026

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced a proposed private placement of $200M aggregate principal amount of Convertible Senior Notes due 2032 to qualified institutional buyers under Rule 144A, with an option for initial purchasers to buy up to an additional $30M within 13 days of issuance. Net proceeds will fund capped call transactions to offset potential dilution and general corporate purposes, including acquisitions, strategic investments, working capital, and capital expenditures. The offering is subject to market conditions, with terms like interest rate and conversion rate to be set at pricing; forward-looking statements highlight risks such as market changes and failure to close.

• ·Notes are general unsecured obligations accruing semiannual interest; conversion at Tandem's election into cash, shares, or combination.
• ·Capped call transactions with option counterparties to cover shares underlying the notes, subject to cap.
• ·Notes and conversion shares unregistered under Securities Act; no offer/sale without exemption.
• ·Announcement date: February 23, 2026; SEC filing date: February 27, 2026.
• ·Maturity: 2032; hedge modifications possible by counterparties through maturity.

27-02-2026

HEI reported full-year 2025 net income of $123 million ($0.71 per diluted share), marking a significant turnaround from a $1.4 billion net loss ($11.23 per share) in 2024, driven by the absence of $1.9 billion in wildfire tort liabilities recorded last year. Core income from continuing operations rose 20% to $149 million ($0.86 per share) from $124 million, though per-share value declined due to a larger share count following September 2024 equity issuance; however, Hawaiian Electric's core net income was nearly flat at $178 million versus $181 million, with Q4 core down 6% to $46 million from $49 million and electric utility revenues declining 4% YoY to $3.1B. The utility achieved a 37% renewable portfolio standard while advancing wildfire safety initiatives and maintaining stable residential bills.

• ·Regulators approved Utility’s Enhanced Wildfire Safety Strategy in December 2025
• ·PUC’s Wildfire Fund Study completed in December 2025
• ·Hawaii’s Historic Wildfire Legislation signed into law in July 2025
• ·Equity issuance in September 2024 increased share count
• ·Conference call held February 27, 2026 at 11:30 a.m. Hawaii time
• ·Return on average common equity 18.0% (twelve months ended Dec 31, 2025)

27-02-2026

Sphere 3D Corp. (NASDAQ: ANY) received notice from Nasdaq on February 26, 2026, confirming it has regained compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This resolves the deficiency initially notified on March 6, 2025. No further actions or ongoing issues related to this rule are mentioned.

• ·Registrant's principal executive offices: 243 Tresser Blvd, 17th Floor, Stamford, Connecticut, United States 06901
• ·Telephone number: (647) 952 5049
• ·IRS Employer Identification No.: 98-1220792
• ·Commission File Number: 001-36532

27-02-2026

AIxC launched Season 2 of its AIxC Hub platform, introducing updated engagement mechanics, Tenki-based features, and ecosystem expansion, with details on playbooks and rewards to be released next week. The company's official X account grew to 53,417 followers, with engagement rates up 94% and total impressions approaching 600,000 over recent weeks. However, AIxC announced it will discontinue BesTrade AI Agent and Digital Asset AI Management modules to focus resources on Real-World Asset (RWA) and Embodied AI (EAI) strategies, including intelligent electric vehicles and AI robotics.

• ·Press release dated February 23, 2026
• ·SEC 8-K filing dated February 27, 2026
• ·Season 2 playbooks, ecosystem rewards, and participation guidelines to be released next week

27-02-2026

Indaptus Therapeutics, Inc. amended its Amended and Restated Certificate of Incorporation, effective February 27, 2026, to increase authorized capital stock to 1 billion shares of common stock ($0.01 par value) and 5 million shares of undesignated preferred stock ($0.01 par value). The amendment also permits stockholder actions by written consent without a meeting, subject to preferred stock rights, as approved by stockholders. No financial impacts or operational changes are disclosed.

• ·Original incorporation date: February 24, 2021
• ·Amendment adopted per Section 242 of Delaware General Corporation Law

27-02-2026

CIMG Inc. announced on February 27, 2026, that it received a letter from Nasdaq on February 23, 2026, stating the Nasdaq Hearings Panel will consider the company's failure to timely file its Form 10-Q for the period ended December 31, 2025, as an additional basis for potential delisting under Nasdaq Listing Rule 5250(c)(1) during the monitor period. The company is working diligently to complete and file the overdue 10-Q, with no immediate impact on the trading of its common stock under the symbol 'IMG' on The Nasdaq Capital Market. This development heightens delisting risks amid ongoing compliance issues.

• ·Company website: http://www.ccmg.tech
• ·IR contact: ir@ccmg.tech, +852 70106695

27-02-2026

Texas Capital Bancshares, Inc. completed a public offering of $400M aggregate principal amount of 5.301% Fixed-to-Floating Rate Senior Notes due February 27, 2032, receiving $398.4M in proceeds before offering expenses. The company intends to use the net proceeds for general corporate purposes, which may include funding the redemption of its 4.000% Subordinated Notes due 2031. The notes bear a fixed interest rate of 5.301% payable semi-annually until February 27, 2031, then transition to a floating rate based on Compounded SOFR plus 1.94% payable quarterly.

• ·Underwriting agreement dated February 24, 2026, with Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and TCBI Securities, Inc. as representatives.
• ·Indenture dated February 27, 2026, with U.S. Bank Trust Company, National Association as trustee.
• ·Offering pursuant to Registration Statement No. 333-277061 filed February 14, 2024, and Prospectus Supplement dated February 24, 2026.
• ·Date of earliest event reported: February 24, 2026; Filing date: February 27, 2026.

27-02-2026

Alan S. Roemer resigned as a director of IN8bio, Inc. and as a member of the Audit and Compensation Committees, effective February 28, 2026, with no disagreements cited regarding the company's operations, policies, or practices. The Board appointed independent director Jeremy Graff as Interim Chair of the Board, effective the same date.

27-02-2026

Blackstone Real Estate Income Trust, Inc. declared February 2026 gross distributions of $0.0544 per share for all classes of its common stock, with net distributions varying by class after stockholder servicing fees (ranging from $0.0451 for Class S/S-2 to $0.0544 for Class I/L). Payments are to stockholders of record as of February 28, 2026, payable on or about March 20, 2026, in cash or via reinvestment. Class C shares have no distribution as they are an accumulating share class.

• ·Declaration date: February 26, 2026
• ·Record date: close of business on February 28, 2026
• ·Payment date: on or about March 20, 2026
• ·Distributions payable in cash or reinvested for participants in the distribution reinvestment plan

27-02-2026

Fold Holdings, Inc. (NASDAQ: FLD) announced the extinguishment of $66.3 million in convertible note obligations through strategic capital transactions, simplifying its capital structure by eliminating all convertible notes and their restrictive covenants. The company released 521 bitcoin from collateral and reduced potential share dilution by an estimated 8.0 to 10.0 million shares. This positions Fold for growth, including the launch of the Fold Credit Card and expansion into enterprise services.

• ·Transactions restore operational and financing flexibility by removing consent requirements and execution friction from prior notes.
• ·Bitcoin treasury can now support operational expenses, credit card warehouse/reserve requirements, or future financing.

27-02-2026

Aviat Networks, Inc. entered into Amendment No. 2 to its Amended and Restated Tax Benefit Preservation Plan with Computershare Inc. on February 27, 2026, extending the plan's final expiration date to March 3, 2029, subject to stockholder ratification at the 2026 annual meeting. The amendment protects the company's Tax Benefits, including net operating losses, which the Board views as valuable assets. If not approved, the plan will terminate upon certification of the voting results.

• ·Original Plan dated August 27, 2020; previously amended February 28, 2023
• ·Filing incorporates Exhibit 4.1: Amendment No. 2

27-02-2026

Xenon Pharmaceuticals Inc. filed a prospectus supplement on February 27, 2026, to register $400M of common shares issuable under its at-the-market equity offering sales agreement with Jefferies LLC and Stifel, Nicolaus & Company, Incorporated, dated August 6, 2020, and amended March 1, 2022. As of the filing date, the company has sold $291.1M in shares under the sales agreement and prior prospectus, which has now been terminated and replaced by the new supplement. No shares have been sold under the new prospectus as of the report date.

• ·Sales agreement originally dated August 6, 2020, and amended on March 1, 2022.
• ·Registration statement on Form S-3 (File No. 333-281451) filed August 9, 2024, with base prospectus dated same day.
• ·Legal opinion on shares provided as Exhibit 5.1 by Blake, Cassels & Graydon LLP.

27-02-2026

Ocular Therapeutix, Inc. disclosed under Regulation FD that slides detailing results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration will be presented at the 49th Macula Society Annual Meeting on February 27, 2026, and made available on the company's investor website at 4:15 pm ET. No specific trial outcomes or financial metrics were included in the filing.

• ·Slides available under Investors section of corporate website
• ·Presentation at 49th Macula Society Annual Meeting

27-02-2026

On February 26, 2026, the Compensation Committee of Iridium Communications Inc. approved the Annual Performance Bonus Plan, making eligible employees including CEO, CFO, and other NEOs eligible for cash or RSU bonuses up to 200% of target based on corporate and individual performance goals for periods starting January 1, 2026. The Committee also adopted the Executive Severance Plan, providing non-CIC severance of 18 months base salary (CEO) or 12 months (other NEOs) plus prorated bonus and COBRA, with enhanced CIC benefits including 2X (CEO) or 1.5X (others) of base plus target bonus and full equity vesting acceleration. These plans are subject to recoupment under the Company's Incentive Compensation Recoupment Policy and will be filed as exhibits to the Q1 2026 10-Q.

• ·Non-CIC severance includes prorated annual target bonus and COBRA premiums for up to 12 months.
• ·CIC severance paid in lump sum with full acceleration of outstanding equity awards.
• ·Plans require execution of waiver/release and compliance with restrictive covenants.

27-02-2026

Northpointe Bancshares, Inc. (NYSE: NPB) announced the appointment of Rodney E. Hood, former Acting Comptroller of the Currency and Chairman of the National Credit Union Administration (NCUA), to the Board of Directors of the Company and its subsidiary Northpointe Bank, effective February 27, 2026. Hood brings nearly three decades of financial services leadership, including roles at the FDIC, FSOC, and FFIEC, to support strategic growth, governance, and risk management. Chairman and CEO Chuck Williams highlighted Hood's expertise in innovation and community value, aligning with the company's focus as a leading mortgage warehouse financing provider.

• ·Headquartered in Grand Rapids, Michigan.
• ·Contacts: Kevin Comps (616-974-8491), Brad Howes (616-726-2585).

27-02-2026

Birchtech Corp. priced an underwritten public offering of 6,250,000 shares at $2.40 per share for gross proceeds of $15M, with a 30-day underwriter option for up to 937,500 additional shares; the offering is expected to close on or about February 27, 2026. Concurrently, the company's common stock was approved for listing on NYSE American, beginning trading under symbol BCHT on February 26, 2026, terminating OTCQB trading while remaining on TSX. Net proceeds, combined with existing cash, will support operating expenses, working capital, and general corporate purposes.

• ·Registration statement on Form S-1 (File No. 333-292701) became effective on February 17, 2026.
• ·Offering managed by joint book-running managers Lake Street Capital Markets, LLC and Huntington Securities, Inc.

27-02-2026

Mitesco, Inc. disclosed via 8-K the execution of a Senior Secured Original Issue Discount Convertible Promissory Note by its subsidiary Amaze Holdings, Inc. to C/M Capital Master Fund, LP, pursuant to a Securities Purchase Agreement, with maturity 18 months from issuance and no interest accruing absent default. The note is secured by a first-priority lien on assets via a Security Agreement and fully guaranteed by subsidiaries, ranking senior to other indebtedness except pari passu with other notes issued under the same agreement. Events of default include payment failures, breaches, bankruptcy, and judgments exceeding $50,000, triggering 10% default interest.

• ·Maturity Date: 18 months from Original Issuance Date
• ·No interest accrues unless Event of Default (then 10% p.a., compounding monthly on 360-day year)
• ·Holder participation right in subsequent financings up to 100% Pro Rata Portion at 10% discount
• ·Cure periods: 10 days for certain breaches
• ·Proceedings undismissed for 45 or 30 days trigger default
• ·Hypothetical exchange example: $100,000 Note portion for Common Stock at 20% effective discount ($4.00 vs $5.00/share)

27-02-2026

IMAC Holdings, Inc. entered into a secured promissory note on February 26, 2026, with a principal amount of $175,000 issued for a purchase price of $125,000, representing a steep 28.6% discount indicative of distressed financing. The note matures upon written demand by the lender and includes standard events of default such as bankruptcy, with no prepayment penalties. No other financial metrics or performance comparisons were disclosed.

• ·Note is secured and includes customary representations, warranties, covenants, and events of default.
• ·Maturity date: upon holder's written demand.

27-02-2026

Lisata Therapeutics, Inc. and Kuva Labs Inc. executed an Amendment to their Binding Term Sheet, effective February 27, 2026, extending the term of the original agreement dated January 20, 2026, from February 28, 2026, to March 7, 2026. No other terms of the Term Sheet were modified, and it remains in full force and effect.

• ·Amendment executed in counterparts.
• ·Original Term Sheet dated January 20, 2026.

27-02-2026

Gogo Inc. reported strong Q4 2025 total revenue of $230.6 million, up 67% YoY and 3% QoQ, driven by the Satcom Direct acquisition, with service revenue up 61% YoY to $191.9 million and equipment revenue up 104% YoY to $38.7 million. However, total ATG aircraft online decreased 9% YoY to 6,402, AVANCE units sold fell 16% YoY/QoQ to 175, ARPU declined 3% YoY to $3,378, and Q4 net income was a loss of $10 million amid litigation costs. Full year 2025 revenue hit $910.5 million, up 105% YoY, with Adjusted EBITDA up 53% to $217.8 million, and the company issued 2026 guidance for revenue of $905-945 million and Free Cash Flow of $90-110 million.

• ·Satcom Direct acquisition closed December 3, 2024; Q4 pro-forma revenue vs Q4 2024 pro-forma of $224.9M (+3%).
• ·First Gogo 5G aircraft activated December 2025; 5G network availability January 2026.
• ·2026 guidance: Net capex $20M assuming $45M FCC reimbursement; Adjusted EBITDA includes $3M strategic investments and $5M litigation expense.

27-02-2026

PRIMEENERGY RESOURCES CORPORATION entered into the Fifth Amendment to its Fourth Amended and Restated Credit Agreement effective February 24, 2026, reaffirming the Borrowing Base at $115M, providing continued liquidity at stable levels. However, the amendment increases Applicable Margins across the Borrowing Base Utilization Grid (e.g., 2.75% SOFR and 1.75% ABR for <25% utilization, up to 3.75% SOFR and 2.75% ABR for >90%), raising borrowing costs, and sets Term SOFR Adjustment to 0.0%. Certain covenant thresholds in Section 8.20 were relaxed from 25% to 30%, while post-closing obligations require mortgages covering 90% of Borrowing Base Value and title information on 85% within 45 days.

• ·Amendment serves as Scheduled Redetermination for December 1, 2025.
• ·Post-closing delivery of Mortgages/Mortgage amendments and title information due within 45 days of February 24, 2026.
• ·Lender Applicable Percentages: Citibank and Fifth Third Bank at 26.521739130% each; others at 15.652173913% each.

27-02-2026

On February 25, 2026, American Tower Corporation's Compensation Committee approved 2026 base salaries and target cash bonus potentials for its named executive officers, including CEO Steven O. Vondran at $1,000,000 base and $2,000,000 target (200% of base), and other executives with bases from $605,000 to $706,200 and 125% targets. Former EVP Olivier Puech retired effective January 2, 2026, and is excluded from the 2026 compensation determinations. Bonuses will be based on company financial goals and individual performance, with potential upside to 200% of target.

• ·Compensation Committee decisions based on pre-established company financial goals and individual objectives, with potential bonus increase up to 200% of target if goals exceeded.
• ·Additional compensation details to be in 2026 Proxy Statement.
• ·Olivier Puech retirement effective January 2, 2026.

27-02-2026

Grid Dynamics Holdings, Inc. (GDYN) adopted Amended and Restated By-Laws effective February 26, 2026, as disclosed in an 8-K filing on February 27, 2026 under Items 5.03 and 9.01. The by-laws address standard governance provisions including stockholder meetings (with detailed advance notice requirements for proposals and nominations), board structure, officer roles, indemnification, amendments, exclusive forum provisions, and electronic notices. No financial metrics, changes, or impacts are mentioned.

• ·By-laws effective February 26, 2026
• ·Stockholder notice deadlines: 90-120 days prior to annual meeting anniversary (Pacific Time)
• ·Special meetings callable by Chairperson or majority Board resolution
• ·Advance notice includes detailed disclosures on ownership, derivatives, agreements, and interests exceeding $100,000 in competitors

27-02-2026

Avis Budget Group, Inc. shareholders are notified of proposed voluntary dismissals, subject to court approval, of two shareholder derivative actions filed in 2025 alleging breaches of fiduciary duties and misleading statements related to the company's February 2025 announcement of accelerated fleet rotation and a non-cash impairment for Q4 2024. The actions, Jones v. Pahwa (filed June 6, 2025) and Dua v. Ferraro (filed September 9, 2025), seek unspecified damages and governance changes but are set to be dismissed without prejudice unless another shareholder intervenes by April 13, 2026.

• ·Court ordered notice on November 24, 2025.
• ·Case numbers: Jones v. Pahwa, No. 2:25-cv-07934-MEF-CF; Dua v. Ferraro, No. 2:25-cv-15382-MEF-CF.
• ·Intervention motions due by April 13, 2026, to Clerk of U.S. District Court for the District of New Jersey, 50 Walnut Street, Room 4015, Newark, NJ 07101.
• ·Complaints available at specified URLs.

27-02-2026

Centerspace (CSR) presented operational updates and 2026 guidance, owning 12,262 apartments across 61 communities with $2.4B total capitalization and shares trading at a 20% discount to consensus NAV as of February 24, 2026. Leasing trends showed normal seasonal patterns with Q1 2026 same-store blended rents down 0.5%, new leases -1.4%, and mixed YTD regional spreads including declines like -3.7% blended in one region; however, 2026 guidance projects same-store revenue growth of 0-1.75% (midpoint 0.88%), NOI -0.5% to 2% (midpoint 0.75%), and Core FFO $4.81-$5.05 per share, outperforming peer midpoints. Portfolio quality improved via 2025 acquisitions (761 homes, 67.4% NOI margin) and dispositions (1,511 homes, 52.9% NOI margin), with favorable relative growth and lower volatility versus multifamily peers.

• ·Well-laddered debt maturity profile with weighted average interest rate of 3.6% and maturity of 6.9 years; net debt to annualized trailing EBITDA at 6.0x most recent quarter.
• ·2026 same-store retention at 50.0% YTD as of February 5, 2026; ORA score of 74.77 vs national average 63.42.
• ·Portfolio weighted average market vacancy 8.7%, YoY rent growth 0.8%; CSR markets show higher projected household (5.4%) and employment growth (2.9%) vs US averages through 4Q31.

27-02-2026

On February 27, 2026, the Board of Directors of Macy’s, Inc. scheduled the annual meeting of stockholders for May 15, 2026, and set the record date for stockholders to vote at the meeting as March 19, 2026. This action was disclosed in an 8-K filing under Item 8.01 Other Events. No financial or operational metrics were reported.

27-02-2026

Saul Centers, Inc. reported Q4 2025 total revenue up 10.6% YoY to $75.1M from $67.9M, driven by higher commercial and residential base rents, but net income declined 21.2% to $8.2M from $10.4M primarily due to a $5.1M adverse impact from Hampden House startup costs including reduced capitalized interest. For the full year 2025, revenue increased 7.8% to $289.8M from $268.8M, while net income fell 27.3% to $49.2M from $67.7M due to initial operations of Twinbrook Quarter Phase I and Hampden House; same property NOI decreased 11.2% in Q4 (Shopping Centers up 1.3%, Mixed-Use down 32.2% due to prior non-recurring income) and 2.0% for the year.

• ·Commercial portfolio occupancy: 94.6% as of Dec 31, 2025 (down from 95.2% prior year)
• ·Residential portfolio occupancy: 97.7% as of Dec 31, 2025 excluding Hampden House apartments (up from 82.8%)
• ·Hampden House opened October 1, 2025; 130/366 residential units (35.5%) leased as of February 23, 2026
• ·Portfolio: 50 shopping centers and 9 mixed-use properties totaling ~10.6M sq ft leasable area; >85% NOI from Washington D.C./Baltimore area
• ·Q4 FFO available to common stockholders and noncontrolling interests: $21.5M or $0.61/share (down from $22.0M or $0.63/share)
• ·Full year FFO: $96.7M or $2.76/share (down from $106.8M or $3.10/$3.09/share)

27-02-2026

Triumph Financial, Inc. (NYSE: TFIN) declared a quarterly cash dividend of $17.81 per share on its 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock, equivalent to $0.44525 per depositary share (NYSE: TFIN-PR). The dividend is payable on March 30, 2026, to holders of record at the close of business on March 15, 2026. No period-over-period comparisons or other financial metrics were provided in the announcement.

• ·Triumph is headquartered in Dallas, Texas.
• ·Company's Annual Report on Form 10-K filed with SEC on February 11, 2026.
• ·Investor Relations: lwyse@tfin.com, 214-365-6936; Media: atavackoli@tfin.com, 214-365-6930.

27-02-2026

Tennant Company (TNC) announced on February 26, 2026, that Barb Balinski, age 62 and Senior Vice President, Chief Transformation Officer, gave notice of her intention to retire effective September 3, 2026. The filing was made on February 27, 2026, under Item 5.02. No immediate successor or additional details on transition plans were disclosed.

• ·Company headquarters: 10400 Clean Street, Eden Prairie, Minnesota 55344-2650
• ·Common Stock: par value $0.375 per share, traded as TNC on NYSE

27-02-2026

Pathfinder Bancorp, Inc. revised its Q4 2025 net loss to $5.6M or $(0.88) per diluted share from the previously reported $7.0M or $(1.11) per share, due to an additional $1.5M non-cash income tax benefit, increasing the Q4 tax benefit to $3.0M. For the full year 2025, the net loss improved to $1.9M or $(0.31) per diluted share from $3.4M or $(0.54) per share, with the annual tax benefit revised to $2.2M. Despite these improvements, the company continues to report net losses for both the quarter and the year.

• ·The $1.5M income tax adjustment is non-cash and reflects updated deferred tax asset analysis as of December 31, 2025.
• ·Corrected financials will be in forthcoming Form 10-K.
• ·Original earnings press release issued January 29, 2026.

27-02-2026

On February 24, 2026, Context Therapeutics Inc. filed a stipulation and proposed consent judgment with the Delaware Court of Chancery to invalidate charter provisions mandating three-year director terms and removal only for cause, resolving a stockholder class action filed by the Vladimir Gusinsky Revocable Trust on February 4, 2026. The company's 2026 annual meeting is scheduled for June 24, 2026, with a record date of April 27, 2026. Stockholders must submit proposals by March 14, 2026, per bylaws, and universal proxy notices by April 13, 2026.

• ·Stockholder proposals must be delivered to: Context Therapeutics Inc, Attn: Secretary, 2001 Market Street, Suite 3915, Unit 15, Philadelphia, PA 19103
• ·Proposal deadline is 5:00 p.m. EDT on March 14, 2026 (90th day prior to first anniversary of 2025 annual meeting)

27-02-2026

On February 25, 2026, PennantPark Floating Rate Capital Ltd. entered into an underwriting agreement with Raymond James & Associates, Inc., as representative of the several underwriters, and PennantPark Investment Advisers, LLC, for the issuance and sale of $200 million aggregate principal amount of 6.75% Notes due 2029. The offering is made pursuant to the company's effective shelf registration statement on Form N-2 (Registration No. 333-279726), supplemented by prospectuses dated February 25, 2026. No period-over-period financial comparisons are provided in the filing.

• ·Underwriting Agreement filed as Exhibit 1.1
• ·Shelf registration statement: Form N-2 (Registration No. 333-279726)
• ·Preliminary prospectus supplement and final prospectus supplement both dated February 25, 2026

27-02-2026

First Foundation Inc. held a special shareholder meeting on February 27, 2026, where stockholders overwhelmingly approved the merger with FirstSun Capital Bancorp under the Agreement and Plan of Merger dated October 27, 2025 (Proposal 1: 63,026,154 votes for, 36,785 against, 52,655 abstain). The advisory merger compensation proposal (Proposal 2) passed with 61,420,708 votes for despite 1,570,317 against, and the amendment to FirstSun’s certificate of incorporation (Proposal 4) was approved with 62,964,438 votes for. The adjournment proposal was withdrawn as unnecessary due to quorum and approvals.

• ·Definitive joint proxy statement/prospectus filed January 15, 2026, supplemented February 6, 2026.
• ·Proposal 3 (adjournment) withdrawn due to quorum and requisite approvals.

27-02-2026

Lesaka Technologies' Remuneration Committee increased Lincoln Mali's annual base salary to ZAR 8,000,000 ($503,176) effective February 1, 2026, and awarded him a one-off bonus of ZAR 3,500,000 ($220,140). The Committee also adopted fiscal 2026 cash incentive awards for executives Steven Heilbron (base $400,000, max $480,000), Lincoln Mali (max ZAR 9,600,000 or $603,812), and Dan Smith (base ZAR 6,750,000, max ZAR 8,100,000 or $509,466), with payouts ranging from 20% to 120% of base salary based on quantitative (30-50% weighting) and qualitative performance factors. No prior period compensation data is provided for comparison.

• ·Quantitative targets include Group Net Revenue (10% allocation for all), Group Adjusted EBITDA (10%), Positive Earnings (10%), with additional targets for Dan Smith (Net Debt:EBITDA 10%, Free Cash Flow Conversion 10%) and Lincoln Mali (Consumer Segment Adj. EBITDA 10%).
• ·Qualitative criteria for Steven Heilbron include M&A objectives (45% of qualitative), Bank Zero integration (15%), and corporate culture (10%).
• ·Exchange rate used: $1 = ZAR 15.8990 as of February 26, 2026.
• ·Remuneration Committee has discretion to adjust awards from 0% to maximum, including to zero.

27-02-2026

FirstSun Capital Bancorp held a special shareholder meeting on February 27, 2026, where stockholders overwhelmingly approved three key proposals related to its merger with First Foundation Inc., including adoption of the merger agreement dated October 27, 2025, an increase in authorized common stock shares, and creation of a new class of non-voting common stock. Proposal 1 (merger approval) passed with 24,390,817 votes for, 21,071 against, 98,685 abstentions, and 485,766 broker non-votes. All proposals received strong support with no significant opposition.

• ·Definitive joint proxy statement/prospectus filed January 15, 2026, supplemented February 6, 2026.
• ·Proposal 4 (adjournment) withdrawn as not needed due to quorum and approvals.
• ·Merger agreement dated October 27, 2025.

27-02-2026

Comcast Corporation's Board of Directors appointed Gordon Smith to the Audit Committee on February 25, 2026, following his prior appointment as a director on February 4, 2026. This governance update was reported in an 8-K filing on February 27, 2026, under Item 5.02. No financial impacts or other changes were disclosed.

27-02-2026

AXIS Capital Holdings reported full-year 2025 gross premiums written (GPW) of $9.6 billion, up 7% YoY from $9.0 billion, with Insurance segment growing 9% to $7.2 billion while Reinsurance increased modestly 3% to $2.4 billion. The company delivered a strong combined ratio of 89.8%, record underwriting income of $597 million in Insurance, and diluted book value per share of $77.20 (up 18.3% over past 12 months), alongside over $1 billion in capital returns to shareholders. However, growth was cautious in lines like Cyber Insurance, Liability Reinsurance, and Motor Reinsurance, with portfolio reshaping in Public D&O, Primary Liability, and Cyber.

• ·Average quarterly loss ratio of 58.9% since Q1 2024, with lower volatility than peers.
• ·Investment portfolio: 78% fixed maturities (4.6% book yield), average duration 3.1 years, 19% allocation to risk assets.
• ·Teams added: NA Environmental (Jan 2024), US Construction (Jan 2024), Ocean Marine (Jun 2024), Life Sciences (Sep 2024).
• ·G&A ratio improved with GPW up 15% since YE2023 while G&A dollars up only 3%.
• ·A.M. Best and S&P financial strength ratings: A+.

27-02-2026

On February 25, 2026, Visa Inc. deposited $125 million into its U.S. litigation escrow account under the U.S. retrospective responsibility plan, triggering downward adjustments to class B-1 and B-2 common stock conversion rates effective February 26, 2026. This reduced the as-converted class B-1 share count by 7,880 (from 7,490,714 to 7,482,834) and class B-2 by 392,202 (from 181,804,989 to 181,412,787), with effects equivalent to repurchasing class A common stock. No declines or flat metrics reported; the action is EPS accretive.

• ·Class B-1 conversion rate adjusted from 1.5491 to 1.5475
• ·Class B-2 conversion rate adjusted from 1.5108 to 1.5075
• ·Adjustments based on volume-weighted average price on February 25, 2026, per certificate of incorporation

27-02-2026

Advanced Drainage Systems, Inc. entered into a Fourth Amendment to its Credit Agreement on February 27, 2026, refinancing in full its existing term loans with new 2026 Refinancing Term Loans equal to the outstanding principal and replacing existing revolving commitments with new 2026 Refinancing Revolving Commitments plus incremental commitments to achieve a total revolving facility of $750M. The amendment also includes $192M in new 2026 Incremental Term Loans and replaces Barclays Bank PLC with PNC Bank, National Association as administrative agent. No performance declines noted, but the transactions increase overall debt capacity.

• ·Refinancing matches aggregate principal of existing term loans and revolving commitments outstanding prior to amendment.
• ·Bank of America, N.A. designated as Term Administrative Agent.
• ·PNC Capital Markets LLC, Bank of America, N.A., and others act as joint lead arrangers and bookrunners.

27-02-2026

Brainstorm Cell Therapeutics Inc. entered into a Securities Purchase Agreement dated February 24, 2026, with an unidentified Purchaser to issue and sell unregistered securities pursuant to Section 4(a)(2) and Regulation D exemptions. Net proceeds are designated for working capital purposes, with covenants including share reservation, listing efforts on Trading Markets, and standard indemnification for the Purchaser. No specific pricing, share counts, or dilution impacts were disclosed in the agreement excerpt.

• ·SEC 8-K filed February 27, 2026, covering Items 1.01 (Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Director/Officer Changes), and 9.01 (Exhibits)
• ·Securities include Shares, Warrants, and Prefunded Warrant Shares
• ·Purchaser identity confidential except as required by law
• ·Prohibitions on use of proceeds for redemptions, litigation settlements, or FCPA/OFAC violations

27-02-2026

Callaway Golf Company reported recast continuing operations results excluding Topgolf and Jack Wolfskin divestitures, with total net sales declining 1.6% YoY to $629.6M in Q1 2025 and 2.3% to $600.4M in Q2, for H1 down 1.9% to $1,230.0M, driven by declines across categories including Golf Balls (-4.5% Q2), Apparel (-6.5% Q2), and Gear (-5.0% Q2), while Apparel, Gear and Other segment sales fell 2.1% in Q1 and 5.8% in Q2. However, Golf Equipment operating income rose 23.8% to $101.8M in Q1 and 11.5% to $178.0M in H1, boosting total operating income 30.8% in Q1 and 7.2% in H1 despite a 14.3% Q2 decline to $74.3M. Gross margins improved slightly to 45.0% in Q1 from 43.5% prior.

• ·Q1 2025 gross margin 45.0% vs 43.5% prior (GAAP), U.S. net sales down 1.5% YoY, Europe up 1.7%.
• ·Q2 2025 Europe net sales up 21.4% YoY to $64.6M, Rest of World flat at $42.8M.
• ·Non-GAAP diluted EPS from continuing ops Q1 2025: $0.30 vs $0.28 prior.
• ·Jack Wolfskin sale closed May 31, 2025; Topgolf 60% sale closed Jan 1, 2026 with 40% retained.

27-02-2026

Bolt Projects Holdings, Inc. disclosed that its independent registered public accounting firm, Elliott Davis, PLLC, resigned effective February 27, 2026, after providing formal notice on February 25, 2026. There were no disagreements on accounting principles, financial disclosures, or auditing procedures, but Elliott Davis' prior audit reports on the 2023 and 2024 financial statements included a going concern qualification and the Company had disclosed material weaknesses in internal controls in its Form 10-K filed March 18, 2025. Elliott Davis furnished a letter to the SEC concurring with the Company's disclosures.

• ·Elliott Davis audited consolidated financial statements as of December 31, 2024 and 2023.
• ·Company is an emerging growth company under Rule 405 and Rule 12b-2.
• ·Securities trade on OTC Pink: Common stock (BSLK), Warrants (BSLKW).
• ·No reportable events under Item 304(a)(1)(v) of Regulation S-K except material weaknesses in 2024 Form 10-K.

27-02-2026

Elite Express Holding Inc. (ETS) reported FY2025 revenue of approximately $2.7 million, up 9.1% YoY from $2.5 million, primarily driven by activity-based revenue increasing to 75.7% of total from 70.2%. However, the net loss widened to $2.2 million from $0.4 million, due to G&A expenses surging 286.1% to $1.6 million from public company compliance costs and new R&D expenses of $0.9 million, while fixed revenue declined 7.8% to $0.6 million. Gross profit saw a slight increase to $18,211 from $15,897.

• ·Company listed on Nasdaq on August 20, 2025.
• ·Loans receivable of $9,999,811 as of Nov 30, 2025, at 8% interest, maturing May 2026.
• ·Cash used in operating activities: $(2,819,786) in FY2025.
• ·Total stockholders’ equity: $13,191,867 as of Nov 30, 2025.

27-02-2026

Carnival Corporation and Carnival plc propose a DLC Unification and Redomiciliation, making Carnival plc a wholly-owned subsidiary of Carnival Corporation (redomiciling from Panama to Bermuda as Carnival Corporation Ltd., ticker CCL on NYSE), eliminating dual listings on NYSE and LSE, and terminating the ADS program. Shareholder meetings, including a UK Court Meeting, are set for April 17, 2026, in Miami (with live video in Southampton), with document requests due by April 10, 2026, and completion anticipated before end of Q2 2026. Boards unanimously recommend approval citing benefits like unified share pricing, enhanced liquidity, index weighting, and reduced administrative/regulatory costs; no material risks or declines highlighted.

• ·Meetings at Carnival Place, 3655 N.W. 87th Avenue, Miami, FL 33178-2428, starting 8:30 a.m. EDT; live video at Carnival House, 100 Harbour Parade, Southampton SO15 1ST, UK, 1:30 p.m. BST.
• ·Contact for documents: ATTENTION: COMPANY SECRETARY, TELEPHONE: (305) 599-2600, EXT. 18019.

27-02-2026

UDR, Inc. filed an 8-K on February 27, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits), attaching Exhibit 99.1. No specific financial metrics, period-over-period comparisons, or performance details (positive, negative, or flat) are provided in the visible content. This filing likely discloses material non-public information, such as preliminary results.

• ·Filing includes Exhibit 99.1 (udr-20260227xex99d1.htm)

27-02-2026

Sable Offshore Corp. reported a full year 2025 net loss of $410.2 million, driven by production restart operating expenses, G&A, and non-cash interest, while ending the year with $921.6 million in short-term debt and $97.7 million in cash equivalents. Positively, the company restarted Santa Ynez Unit production on May 19, 2025, completed pipeline repairs and hydrotests, raised $295 million via a public offering in May and $250 million via a private placement in November, and secured regulatory progress from PHMSA including an emergency special permit. However, no commercial hydrocarbon sales have occurred since acquisition, with oil stored pending pipeline resumption or OS&T implementation.

• ·Senior Secured Term Loan maturity extended to earliest of March 31, 2027 or 90 days after first hydrocarbon sales via Second Amendment on November 24, 2025.
• ·PHMSA concurred Santa Ynez Pipeline System is interstate and 'active' on December 17, 2025, and issued emergency special permit for segments 324/325 on December 23, 2025.

27-02-2026

DTE Gas Company reported strong 2025 financial results with operating revenues up 14% YoY to $2.033B and net income up 14% to $296M, primarily driven by favorable weather (+$119M), gas cost recovery (+$111M), and implementation of new rates (+$86M). However, base sales declined $27M, the infrastructure recovery mechanism contributed negatively (-$64M), and end-user transportation volumes decreased 2% YoY to 164 Bcf while 2024 net income had declined 12% from 2023. The company filed a rate case on November 13, 2025 with the MPSC seeking a $163M net base rate increase and ROE of 10.25%, with a final order expected in September 2026.

• ·Cost of gas expense up $111M YoY in 2025 primarily due to higher volumes (+$101M) and higher gas costs (+$10M).
• ·Operation and maintenance expense up $71M YoY in 2025, driven by higher gas operations ($54M) and corporate costs.
• ·Total assets increased to $8.905B as of Dec 31, 2025 from $8.394B in 2024.
• ·Rate case projects revenue deficiency of $238M, net of $75M IRM roll-in.

27-02-2026

Carnival Corporation and Carnival plc propose DLC Unification and Redomiciliation transactions to unify their dual-listed structure under Carnival Corporation Ltd. (redomiciled from Panama to Bermuda) with a single NYSE listing under ticker CCL, eliminating the LSE listing and ADS program. Shareholder meetings, including a Carnival plc Court Meeting and General Meetings for both companies, are set for April 17, 2026, at Carnival Place in Miami, with completion anticipated before the end of Q2 2026 if approved. The Boards unanimously recommend approval, citing benefits such as a single global share price, improved liquidity, reduced administrative costs, and simplified corporate actions; no material risks or downsides are highlighted in the filing.

• ·Request incorporation documents by April 10, 2026, via Company Secretary at (305) 599-2600, ext. 18019.
• ·Carnival plc Court Meeting at 8:30 a.m. EDT, followed by General Meetings, at 3655 N.W. 87th Avenue, Miami, FL 33178; live video broadcast at Carnival House, Southampton, UK, 1:30 p.m. BST.
• ·Conditions include court sanction, shareholder approvals, and regulatory clearances.

27-02-2026

Ares Capital Corporation, acting as servicer and transferor for borrower Ares Capital JB Funding LLC, entered into Amendment No. 13 to its Loan and Servicing Agreement on February 25, 2026, increasing the maximum facility amount from $1.3B to $1.6B USD with lenders SMBC, Citizens Bank, N.A., and Sumitomo Mitsui Trust Bank, Limited, New York Branch. The amendment confirms no Events of Default, Unmatured Events of Default, or Servicer Termination Events are occurring. This expands borrowing capacity under the revolving credit facility originally dated January 20, 2012.

• ·Amendment effectiveness conditioned on payment of outstanding fees, delivery of executed signatures, opinions of counsel, and Borrower's payment of Administrative Agent's legal fees.
• ·Original Loan and Servicing Agreement dated January 20, 2012; prior amendments include No. 12 on July 25, 2025, No. 11 on December 6, 2024.

27-02-2026

Wyndham Hotels & Resorts, Inc. entered into a Seventh Supplemental Indenture on February 27, 2026, to issue $650M aggregate principal amount of 5.625% senior notes due 2033. Net proceeds were used to repay all outstanding borrowings under its term loan A and revolving credit facility, related fees, and for general corporate purposes. The notes are senior unsecured obligations, equal in right of payment to existing senior debt like the 4.375% notes due 2028, and guaranteed by certain domestic subsidiaries.

• ·Interest payable semi-annually in arrears on March 1 and September 1, commencing September 1, 2026.
• ·Optional redemption prior to March 1, 2029 at make-whole price or up to 40% of principal with equity offering proceeds; thereafter at 102.813% (2029), 101.406% (2030), and 100.000% (2031+).
• ·Change of Control Triggering Event requires repurchase offer at 101% of principal.
• ·Covenants restrict incurrence of liens-secured debt and sale-leaseback transactions.
• ·Notes effectively subordinated to secured credit facilities and structurally to non-guarantor subsidiaries' obligations.

27-02-2026

On February 26, 2026, Claire D’Oyly-Hughes Johnson resigned from the Board of Directors of Aurora Innovation, Inc., effective February 27, 2026, with no disagreements on operations, policies, or practices. Effective the same date, David Wehner, age 56 and Chief Strategy Officer at Meta Platforms, Inc. (formerly Facebook, Inc.), was appointed as a new director with a term expiring at the 2027 Annual Meeting of Stockholders. Mr. Wehner, with prior experience as CFO of Meta Platforms and Zynga Inc., is eligible for $60,000 in annual cash compensation plus equity awards under the Director Compensation Policy.

• ·David Wehner holds an M.S. in applied physics from Stanford University and a B.S. in chemistry from Georgetown University.
• ·No arrangements or understandings led to Mr. Wehner's appointment; no family relationships with other directors or officers.
• ·Company to enter standard indemnification agreement with Mr. Wehner.

27-02-2026

MOZAYYX Acquisition Corp., a blank check company, announced the pricing of its upsized initial public offering of 26,100,000 units at $10.00 per unit, raising $261M. Units are expected to list on the NYSE under 'MZYX.U' beginning February 25, 2026, with separate trading of Class A ordinary shares ('MZYX') and warrants ('MZYX.WS') thereafter. Cantor Fitzgerald & Co. served as sole book-running manager, with a 45-day underwriters' option for up to 3,915,000 additional units.

• ·Registration Statement on Form S-1 (333-293134) declared effective February 24, 2026.
• ·Company incorporated as exempted company under Cayman Islands laws, seeking merger or business combination.
• ·Press release dated February 24, 2026; SEC 8-K filed February 27, 2026.

27-02-2026

ClearThink 1 Acquisition Corp., a blank check company targeting financial services, priced its $125M initial public offering of 12,500,000 units at $10.00 per unit, expected to list on NASDAQ under CTAAU starting February 24, 2026, with separate trading for shares (CTAA) and rights (CTAAR) thereafter. The offering, led by D. Boral Capital LLC, includes a 45-day over-allotment option for 1,875,000 additional units and is set to close on February 25, 2026, subject to customary conditions. No declines or flat metrics reported as this is an IPO pricing announcement.

• ·Registration statement effective February 13, 2026.
• ·U.S. counsel: Ruskin Moscou Faltischek, P.C.; Cayman counsel: Ogier (Cayman) LLP; Underwriters' counsel: Sichenzia Ross Ference Carmel LLP.
• ·SPAC focus: financial services sector in the United States and other developed countries.

27-02-2026

Coffee Holding Co., Inc. amended the Amended and Restated Employment Agreement of Executive Andrew Gordon, effective February 1, 2026, setting his annual base salary at $80,000 (potentially a reduction from prior levels). The amendment adds a $1.6M incentive bonus eligible for payment if Gordon remains employed until January 1, 2030, with full acceleration on termination without Cause or for Good Reason, and pro-rated for disability or death. No other financial performance metrics or period-over-period comparisons are provided.

• ·Incentive bonus payable within 74 days after January 1, 2030, if employed continuously from January 1, 2026.
• ·Full incentive bonus accelerates on termination without Cause or resignation for Good Reason, payable within 30 days without release requirement.
• ·Pro-rated bonus for disability or death based on full calendar quarters from January 1, 2026 (e.g., 8/16 quarters = 50%).
• ·Severance benefits require signed release within 21 days of termination, without imposing non-compete or confidentiality on Executive.
• ·Amendment signed February 2, 2026 (Gordon) and February 26, 2026 (Company), filed February 27, 2026.

27-02-2026

Apple Hospitality REIT (APLE) reported FY 2025 comparable hotels revenue of $1.4B, down 1.1% YoY, with RevPAR declining 1.6% to $117.95, Occupancy down 1.6% to 74.1%, and Adjusted Hotel EBITDA margin contracting 190 bps to 34.3% amid softer demand. Q4 2025 showed steeper declines with RevPAR down 2.6% YoY to $106.90 and EBITDA down 8.4%, though the company repurchased 4.6M shares for $58.3M, maintained a strong balance sheet with $1.5B net debt (35% to total cap), and achieved TSR outperformance of +20.1 ppts vs. MSCI US REIT Index over 2022-2024. Preliminary January 2026 RevPAR declined ~1.5% YoY, but fundamentals remain solid with 59% of hotels facing no new supply nearby.

• ·Portfolio includes 217 hotels across 37 states and 84 markets, 99% rooms-focused with average effective age of 6 years and 4.3 average Tripadvisor rating.
• ·Acquired 6 hotels in 2023, 2 in 2024, 2 in 2025 (3 under contract); sold 6 in 2024 and 7 in 2025.
• ·64% of outstanding debt effectively fixed; $587M availability under revolving credit facility.
• ·59% of hotels have no new supply under construction within 5-mile radius.
• ·Annualized distribution $0.96 per share; average trading volume TTM 1/31/2026: 2.9M shares/day.

27-02-2026

GE HealthCare Technologies Inc. entered into a 364-day revolving credit agreement dated February 26, 2026, providing a $500M revolving credit facility to enhance liquidity. JPMorgan Chase Bank, N.A. serves as administrative agent, with Citibank, N.A., BofA Securities, Inc., BNP Paribas Securities Corp., Goldman Sachs Bank USA, and Morgan Stanley Senior Funding, Inc. as joint bookrunners and lead arrangers. No performance metrics or comparisons are provided in the filing.

• ·Facility includes ABR Loans denominated in Dollars and Term Benchmark Borrowings in Agreed Currencies (Dollars, Euros, Sterling).
• ·Availability Period: from Closing Date to earlier of Final Maturity Date or termination of Commitments.

27-02-2026

Gentherm Incorporated and its subsidiaries entered into the First Amendment to the Second Amended and Restated Credit Agreement on February 24, 2026, amending provisions of the original June 10, 2022 agreement and adding a new Pari Passu Intercreditor Agreement exhibit. The amendment facilitates releases of certain borrowers and guarantors, including Gentherm Enterprises GmbH, Gentherm Licensing GmbH, Gentherm Licensing Limited Partnership (via mergers/dissolution), Gentherm Holding (Malta) Limited, Gentherm Automotive Systems (Malta) Limited (planned liquidation), and Gentherm Properties I, LLC (dissolved), with remaining obligations assumed by other loan parties. No changes to overall borrowing capacity or financial terms were specified.

• ·Original Credit Agreement dated June 10, 2022.
• ·Maltese Release letter agreement dated October 10, 2025.
• ·Administrative Agent to execute release documents at Company's expense.

27-02-2026

On February 24, 2026, Hadar Levy, a Class I director on the Board of Directors of Lifeward Ltd., notified the company of his decision to step down from the Board, effective immediately. His departure did not result from any disagreement with the company's operations, policies, or practices. The company expressed gratitude for his distinguished service and contributions.

• ·Filing date: February 27, 2026
• ·Company address: 2 Cabot Rd., Hudson, MA 01749
• ·Trading symbol: LFWD (Nasdaq Capital Market)

27-02-2026

FTI Consulting reported record Q4 2025 revenues of $990.7M, up 11% YoY from $894.9M, and full-year 2025 revenues of $3.789B, up 2% YoY from $3.699B, driven by strong growth in Corporate Finance (+26.1% Q4) and Strategic Communications (+14.8% Q4). However, full-year net income declined to $270.9M from $280.1M due to higher costs and taxes, Economic Consulting revenues fell 14.5% YoY in Q4 to $176.2M, Technology segment saw full-year declines, and cash from operations dropped sharply to $152.1M from $395.1M. The company repurchased $858.6M in shares for the year and issued 2026 guidance for revenues of $3.94B-$4.1B and EPS of $8.90-$9.60.

• ·Q4 Adjusted EBITDA $106.2M (10.7% margin) vs $73.7M (8.2%) prior year
• ·Full year 2025 EPS $8.24 (includes $0.59 special charge impact) vs $7.81 prior; Adjusted EPS $8.83 vs $7.99 (+11%)
• ·Cash and cash equivalents declined to $265.1M from $660.5M YoY; total debt net of cash $99.9M
• ·$491.8M remains available under stock repurchase program as of Dec 31, 2025
• ·Over 8,100 employees in 32 countries as of Dec 31, 2025

27-02-2026

HA Sustainable Infrastructure Capital, Inc. issued $600M aggregate principal amount of 7.125% Green Junior Subordinated Notes due 2056 on February 27, 2026, under an amended indenture with guarantees from several subsidiaries. Net proceeds will repay portions of revolving credit facility borrowings, commercial paper, or 8.00% Senior Notes due 2027, with ultimate allocation to eligible green projects within two years. The notes feature a fixed 7.125% rate until November 15, 2031, then reset at Five-year U.S. Treasury Rate plus 3.478% (floor 7.125%), but are junior subordinated with deferrable interest payments.

• ·Interest payments semi-annually on May 15 and November 15, commencing May 15, 2026.
• ·Notes subordinate to senior indebtedness and effectively junior to secured debt and subsidiary liabilities.
• ·Redemption options include 101% for Change of Control, 100% after specified dates or Tax Event, and 102% for Rating Agency Event.

27-02-2026

Yelp Inc. reported Q4 2025 net revenue of $360M, down 1% YoY from $362M due to lower RR&O advertising revenue, though partially offset by Services growth; full-year 2025 net revenue reached a record $1.46B, up 4% YoY, with Services advertising up 8% to $948M but RR&O down 6% to $444M. Net income for Q4 was $38M (down 10% YoY) and full-year $146M (up 10% YoY), while Adjusted EBITDA declined 15% to $86M in Q4 but rose 3% to $369M for the year; outlook for 2026 projects net revenue of $1.455B-$1.475B.

• ·Acquired Hatchify Inc., an AI lead management platform.
• ·Signed agreement with OpenAI.
• ·2026 Outlook: Net revenue $1.455B to $1.475B; Adjusted EBITDA $310M to $330M.
• ·Q4 share repurchases: 2.9M shares for $88.5M.
• ·Cumulative reviews reached 330M with 22M new reviews in 2025.
• ·App unique devices down 2% YoY.
• ·Request-a-Quote projects up ~15% YoY excluding paid search.

27-02-2026

Binah Capital Group, Inc. amended the terms of its Series B Junior Convertible Preferred Stock via an Amended Certificate of Designation, allowing dividends payable in cash (with up to 50% in additional shares if no senior default under the Credit Agreement with Byline Bank exists). The Compensation Committee granted CEO Craig Gould 94,828 fully vested restricted shares of common stock valued at $220,000 and approved $350,000 annual incentive bonuses each for Gould and David Shane for FY 2025; it also amended Shane's employment agreement to extend the initial term to five years. No declines or flat performance noted in disclosed metrics.

• ·Series B Subscription Agreement dated September 4, 2024; original Certificate of Designation filed November 14, 2024
• ·Credit Agreement with Byline Bank dated December 23, 2024
• ·Executive employment agreements dated August 14, 2024 (Gould and Shane)
• ·Subordination agreement entered February 26, 2026
• ·Warrants exercisable at $11.50 per share

27-02-2026

Disc Medicine, Inc. approved a restructuring plan on February 26, 2026, to reduce its workforce by approximately 20%, primarily in commercial and supporting functions, following an FDA complete response letter on February 13, 2026, for its bitopertin New Drug Application. The company expects $2.0 million in aggregate charges, mainly severance, to be recorded primarily in Q1 2026, with implementation completing in Q2 2026. This move aligns the workforce with near-term priorities amid the regulatory setback.

• ·Restructuring primarily affects commercial functions and certain supporting functions.
• ·FDA complete response letter dated February 13, 2026, for bitopertin NDA treating erythropoietic protoporphyria and X-linked protoporphyria.
• ·Actual costs may differ from estimates due to assumptions and potential additional expenses.

27-02-2026

Monolithic Power Systems, Inc. announced that its previously issued FY2024 10-K and 2025 10-Q financial statements should no longer be relied upon due to an error in accounting for deferred income taxes on a foreign tax incentive, requiring restatement with a $195M reduction in income tax benefit and net income decreasing $195M (10.9%) to $1.59B for FY2024. While non-GAAP metrics remain unchanged and there is no impact on revenue ($2.21B), operations, or FY2026 outlook, the 2025 unaudited results see a minor $5.6M increase in net income to $621M. The error was unintentional, non-cash, and discovered during 2025 10-K preparation; restated financials will be in the upcoming 2025 10-K.

• ·Non-GAAP net income unchanged at $690M for FY2024 and $858M for FY2025.
• ·FY2024 diluted EPS restated to $32.60 from $36.59 (-10.9%).
• ·Restated financials to be filed in 2025 Form 10-K immediately after this 8-K.
• ·No impact on revenue, gross profit, operating income, or key non-GAAP operational metrics.

27-02-2026

Whirlpool Corporation announced concurrent public offerings of common stock and depositary shares (each 1/20th interest in Series A Mandatory Convertible Preferred Stock), anticipating $800M in aggregate proceeds to repay revolving credit facility debt and fund general corporate purposes, including strategic investments in vertical integration and automation. The Preferred Stock carries a $1,000 liquidation preference per share and automatically converts into common stock around February 15, 2029. In 2025, Whirlpool reported approximately $16B in annual net sales (close to 90% in the Americas), 41,000 employees, and 35 manufacturing and technology research centers.

• ·Underwriters grant 30-day overallotment option for additional Common Stock and Depositary Shares.
• ·Depositary Shares to be listed on NYSE under symbol 'WHR.PRA'.
• ·Announcement dated February 23, 2026; automatic conversion of Preferred Stock on or about February 15, 2029.

27-02-2026

Precipio's fiscal 2025 revenues grew 30% YoY to $24.0M from $18.5M in 2024, with Q4 2025 revenues at $6.7M, up 23% from $5.4M in Q4 2024. Adjusted EBITDA turned positive at $1.23M for full year 2025 (vs -$1.5M in 2024) and $0.95M in Q4 2025 (vs $0.40M in Q4 2024). Operating cash flow improved to $688K for 2025 from $439K in 2024, with adjusted operating cash flow at $727K excluding unusual items.

• ·Q4 2025 EBITDA (non-GAAP) of $0.9M vs $0.0M in Q4 2024.
• ·Shareholder call planned in early April 2026 following 10-K filing.
• ·Adjusted operating cash flow for Q4 2025 was $617K excluding unusual items.

27-02-2026

On February 26, 2026, Dipanjan Deb resigned as a member of the Board of Directors of GoodRx Holdings, Inc., effective immediately. Mr. Deb indicated that his decision was not due to any disagreement with the Company on matters relating to its operations, policies, or practices. The resignation was reported in an 8-K filing dated February 27, 2026.

27-02-2026

Corning Incorporated filed an 8-K under Regulation FD Disclosure announcing that Executive Vice President and CFO Edward Schlesinger will speak at the Morgan Stanley Technology, Media & Telecom Conference on March 3, 2026, at 11:30 AM ET, providing business updates. A live audio webcast of the presentation will be available on investor.corning.com under Events and Presentations, with replay and transcript accessible for 12 months following the event.

• ·Conference webcast replay and transcript available for 12 months post-presentation

27-02-2026

Miluna Acquisition Corp entered into an Indemnification Agreement with Yajuan Ding on February 25, 2026, to indemnify him against liabilities arising from his service as a director or officer, including expenses, judgments, and settlements, subject to exceptions for willful neglect, default, or fraud. The agreement provides for advancement of expenses within 30 days of request and detailed procedures for determining indemnification entitlement. No financial metrics or performance data are disclosed.

27-02-2026

On February 26, 2026, Jupiter Neurosciences, Inc. received Nasdaq notices for non-compliance with the Minimum Bid Price Requirement (closing bid price < $1.00 for 30 consecutive business days from January 13 to February 25, 2026) and the MVLS Requirement (market value of listed securities below $35M for the same period), both critical for continued listing on Nasdaq Capital Market. However, the Company has 180 calendar days until August 25, 2026, to regain compliance by meeting $1.00 bid for 10+ consecutive business days and $35M MVLS for 10 consecutive days, with trading continuing uninterrupted under ticker JUNS. The Company plans to monitor and may pursue options like a reverse stock split, though success is uncertain.

• ·Nasdaq may require bid price maintenance beyond 10 days, up to 20 consecutive business days.
• ·Eligibility for second 180-day compliance period requires meeting MVLS and other initial listing standards (except bid price) and notifying intent to cure, potentially via reverse stock split.
• ·Designated disclosure channels: website https://jupiterneurosciences.com, X @jupiterneuro, Instagram @Nugevia.
• ·Address: 1001 North US HWY 1, Suite 504, Jupiter, FL 33477; Phone: (561) 406-6154.

27-02-2026

Ensysce Biosciences, Inc. received a Nasdaq deficiency notice on February 25, 2026, stating non-compliance with Listing Rule 5550(a)(2) as the common stock bid price closed below $1.00 for 30 consecutive business days. The company has 180 calendar days until August 24, 2026, to regain compliance by achieving a minimum bid price of $1.00 for at least 10 consecutive business days, with no immediate impact on trading under symbol ENSC. Failure to comply could lead to delisting, impairing liquidity, capital raising, and stock value.

• ·Company intends to monitor bid price and evaluate options like reverse stock split if needed
• ·Possible second 180-day compliance period if initial period fails and other standards met
• ·Delisting appeal possible to Nasdaq hearings panel, but no assurance of success

27-02-2026

On February 25, 2026, DNOW Inc. Board member Rodney Eads notified the company of his intention not to stand for reelection at the 2026 annual meeting of stockholders, with his term expiring on the meeting date. The departure is not due to any disagreement with the company's operations, policies, or practices. The Board thanked Mr. Eads for his service.

• ·Company headquartered at 7402 North Eldridge Parkway, Houston, Texas 77041
• ·Common Stock traded on NYSE under ticker DNOW

27-02-2026

Royal Caribbean Cruises Ltd. completed a $2.5B senior notes offering, consisting of $1.25B 4.750% Notes due 2033 and $1.25B 5.250% Notes due 2038, generating net proceeds of approximately $2.471B. The company intends to use the proceeds primarily to refinance senior notes maturing in 2026 and for repaying other existing indebtedness, including term loans. No performance declines or flat metrics are reported in this debt issuance filing.

• ·Underwriting agreement dated February 12, 2026.
• ·2033 Notes interest accrues at 4.750% per annum, payable semi-annually on May 15 and November 15, beginning November 15, 2026; matures May 15, 2033.
• ·2038 Notes interest accrues at 5.250% per annum, payable semi-annually on February 27 and August 27, beginning August 27, 2026; matures February 27, 2038.
• ·Issued pursuant to Base Indenture dated July 31, 2006, supplemented by Fifth Supplemental Indenture dated February 27, 2026.

27-02-2026

The Children’s Place, Inc. appointed Kim Roy, 67, as Executive Director and board member effective March 2, 2026, until the 2026 annual stockholder meeting. Ms. Roy has extensive experience leading multi-billion dollar brands at Ralph Lauren Corporation (Group President North America), Ann Taylor (President), Liz Claiborne, Inc. (Group President), and Associated Merchandising Corporation (SVP General Merchandise Manager). Compensation includes an annual base salary of $600,000, target performance bonus of 75% of base salary, and a sign-on award of 120,000 restricted stock units.

• ·Appointment announced February 23, 2026; employment on at-will basis
• ·No arrangement or understanding with any other person for the appointment
• ·Letter Agreement to be filed as exhibit to Form 10-K for fiscal year ended January 31, 2026

27-02-2026

On February 27, 2026, Robert M. Williams, Jr. resigned as a Class I director of Aveanna Healthcare Holdings Inc. (AVAH), effective immediately, with no disagreement on the company's operations, policies, or practices. Prior to his resignation, Mr. Williams served on the Nominating and Corporate Governance Committee, the Compensation Committee, and the Clinical Quality and Compliance Committee. The filing was signed by Jeff Shaner, Chief Executive Officer.

• ·Company headquartered at 400 Interstate North Parkway SE, Atlanta, Georgia 30339.
• ·Registrant is a Delaware corporation with IRS Employer Identification No. 81-4717209 and Commission File Number 001-40362.

27-02-2026

Tenon Medical, Inc. received a Nasdaq notification letter on February 25, 2026, stating that its common stock (TNON) failed to maintain a minimum $1.00 closing bid price for 30 consecutive business days from January 9 to February 24, 2026, violating Listing Rule 5550(a)(2). The company has an initial 180-day compliance period until August 24, 2026, to achieve $1.00 for 10 consecutive business days, with potential for a second 180-day extension if other listing standards are met. While listing remains intact with no immediate delisting, failure to comply risks suspension and transfer from The Nasdaq Capital Market.

• ·Securities registered: Common Stock (TNON) and Warrants (TNONW) on Nasdaq.
• ·Company is an emerging growth company.
• ·Nasdaq requires public announcement under Listing Rule 5810(b).

27-02-2026

Invitation Homes' March 2026 investor presentation highlights a fortress balance sheet with $1.7B liquidity, 5.3x net debt to TTM adjusted EBITDA, and no debt maturities before June 2027, alongside the accretive acquisition of ResiBuilt expected to contribute $0.02 per share to 2026 AFFO and superior same-store NOI growth of +64.3% since 2017 versus peers. Same-store blended rental rate growth for Jan-Feb 2026 slowed to 1.5% from 1.8% in 4Q 2025, driven by new lease declines of -3.4% despite outpacing multifamily peers and maintaining 96.0% average occupancy. The presentation underscores structural demand for single-family rentals, with ~93% of SFR homes owned by small operators and an implied valuation of ~$270k per home at ≥7% cap rate.

• ·No debt maturities before June 2027; secured debt / gross RE assets at 6.1% (<10% target)
• ·JV & 3PM platform manages 24,000 homes with $87M FY2025 revenue and ~$0.01 accretion per 3,000 homes added
• ·95.9% same-store average occupancy rate and 79% average renewal rate as of 12/31/2025
• ·>39 months same-store average resident tenure; 4.09/5.0 cumulative Google/Yelp rating
• ·Atlanta represents 13% of 4Q25 revenue; primary focus on infill locations in high-growth markets

27-02-2026

On February 25, 2026, affiliates of Amberjack Capital Partners, L.P. (Selling Stockholders) entered into an Underwriting Agreement with J.P. Morgan Securities LLC and others to sell 5,750,000 shares of Innovex International, Inc. (INVX) common stock at $25.75 per share, with the full 30-day option for 862,500 additional shares exercised, totaling 6,612,500 shares sold. The Company repurchased 575,000 of these shares from the Underwriters for approximately $14.1 million under its existing share repurchase program, leaving $76.6 million remaining in authorization; the Company received no proceeds from the stockholder sale.

• ·Underwriting Agreement dated February 25, 2026; Offering closed February 27, 2026
• ·Pursuant to effective S-3 shelf registration (File No. 333-282178, effective October 1, 2024)
• ·Share Repurchase approved by independent committee of the Board

27-02-2026

On February 24, 2026, Collin McQuiddy notified Enhabit, Inc. of his resignation as Senior Vice President and Chief Accounting Officer, effective March 27, 2026, to pursue another career opportunity, with no disagreements regarding company operations, policies, or practices. Ryan Solomon, the Company's Chief Financial Officer, will assume the functions of principal accounting officer on an interim basis without additional compensation or adjustments. Mr. Solomon has no family relationships with directors or executives and was not selected under any special arrangement.

• ·Filing date: February 27, 2026
• ·Date of earliest event reported: February 24, 2026
• ·Mr. McQuiddy will assist with transition through March 27, 2026
• ·Biographical information for Mr. Solomon available in 2025 Proxy Statement
• ·No related party transactions for Mr. Solomon under Item 404(a) of Regulation S-K

27-02-2026

Aardvark Therapeutics voluntarily paused its Phase 3 HERO trial (NCT06828861) and open-label extension (NCT07197034) evaluating ARD-101 for hyperphagia in Prader-Willi Syndrome due to reversible cardiac observations at above-target therapeutic doses in a healthy volunteer study. The company is conducting a comprehensive data review out of caution, halting enrollment and dosing, and no longer anticipates topline data in Q3 2026, planning further guidance in Q2 2026. While prioritizing patient safety and committing to advance the ARD-101 program with optimal dosing, this pause represents a significant delay in the clinical timeline.

• ·ARD-101 granted FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Prader-Willi Syndrome (PWS).
• ·Aardvark developing ARD-201 as fixed-dose combination of ARD-101 with DPP-4 inhibitor in two Phase 2 trials.
• ·Risk factors detailed in 10-Q for quarter ended September 30, 2025, filed November 13, 2025.

27-02-2026

Hashdex Nasdaq Crypto Index US ETF filed an 8-K disclosing Amendment #1 to its Authorized Participant Agreement with Virtu Americas LLC and sponsor Hashdex Asset Management Ltd., dated February 24, 2026. The amendment replaces the Procedures Handbook in full, updates the agreement summary, adds Section 16 for optional in-kind transactions using digital assets for Creation Unit creations/redemptions (minimum 10,000 Shares), and addresses regulatory changes, fees, taxes, and settlement procedures. No financial impacts or performance metrics are disclosed.

• ·Original Authorized Participant Agreement dated January 14, 2025.
• ·SEC Registration Statement No.: 333-280990.
• ·Purchase Order cut-off time: 3:00 P.M. Eastern.
• ·Standard settlement: T+1 business day following purchase order date.

27-02-2026

Prothena Corporation plc announced a share repurchase plan authorizing up to $100M of its ordinary shares, expiring December 31, 2026, with repurchases potentially via open market under Rule 10b-18 or Rule 10b5-1 plans. As of December 31, 2025, the company reported $308.4M in cash, cash equivalents, and restricted cash with no debt, expecting approximately $255M at 2026 year-end excluding repurchases. The guidance excludes potential up to $105M in clinical milestone payments from partners Novo Nordisk (coramitug for ATTR amyloidosis) and Bristol Myers Squibb (PRX019 for neurodegenerative diseases).

• ·Ordinary shares have par value $0.01 per share.
• ·Share Repurchase Plan may be suspended or discontinued at any time without obligation to acquire shares.
• ·Pipeline targets include Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, ALS, and other neurodegenerative diseases.

27-02-2026

VERAXA Biotech AG shareholders approved the merger with Veraxa Biotech Holding AG and an ordinary capital increase of up to CHF 223,400 at their EGM on February 27, 2026, advancing the business combination with Voyager Acquisition Corp. (NASDAQ: VACH). The approvals are prerequisites for closing, subject to Voyager shareholder approval, after which the combined entity will trade on NASDAQ under 'VRXA'. No financial performance metrics or declines were reported, highlighting progress without disclosed setbacks.

• ·Business Combination Agreement signed on April 22, 2025.
• ·Proxy statement/prospectus filed with SEC on February 19, 2026.
• ·Merger via absorption: Veraxa Biotech Holding AG acquires VERAXA and renames to Veraxa Biotech AG.

27-02-2026

Energy Vault Holdings, Inc. issued an additional $10M in 5.250% Convertible Senior Notes due 2031 (Option Notes) to initial purchasers Jefferies LLC, Cantor Fitzgerald & Co., and Citigroup Global Markets Inc., bringing the total notes outstanding to $150M following the initial $140M issuance on February 17, 2026. The company entered into additional capped call transactions to reduce potential dilution upon conversion, with a cap price of $8.12 per share (100% premium over the February 11, 2026 closing price of $4.06). Proceeds from the initial notes were used to repay $45M in senior unsecured convertible debentures to YA II PN, Ltd. on February 19, 2026.

• ·Notes sold in transaction exempt from Securities Act registration requirements
• ·Additional Capped Call Transactions cover shares initially underlying the Option Notes, subject to customary adjustments
• ·Company does not intend to file registration statement for resale of Notes or shares issuable upon conversion
• ·Purchase Agreement dated February 11, 2026

27-02-2026

Cycurion, Inc. adjourned its special stockholder meeting from February 26, 2026, to March 19, 2026, at 12:00 p.m. ET due to insufficient quorum to approve the issuance of up to 3,314,920 shares of common stock upon exercise of warrants from a December 5, 2025, private placement, as required by Nasdaq Listing Rule 5635(d) for issuances potentially exceeding 20% of outstanding shares. The record date remains January 21, 2026, and previously submitted proxies will be honored unless revoked; the company urges non-voting stockholders to vote promptly via instructions in the February 2, 2026, proxy statement or contact D.F. King & Co., Inc.

• ·Proxy statement filed with SEC on February 2, 2026
• ·Investor relations contact: (888) 341-6680, investors@cycurion.com
• ·Media relations contact: (888) 341-6680, media@cycurion.com

27-02-2026

Intuitive Machines, Inc. entered into a Registration Rights Agreement dated February 27, 2026, with investors party to a Securities Purchase Agreement dated February 25, 2026, providing for the registration of resale of Registrable Securities (shares issued thereunder). The Company is required to file a Registration Statement with the SEC no later than April 1, 2026, and use commercially reasonable efforts to have it effective within 30-60 days, maintaining effectiveness for up to five years from the Closing Date, subject to limited suspension periods. No financial metrics or performance data are disclosed in the agreement.

• ·Effectiveness targets: 30 days post-filing if no SEC review, 60 days if reviewed
• ·Allowed Delays: up to 45 consecutive days or 60 total calendar days in any one-year period, not more than two per year
• ·Effectiveness Period: until no Registrable Securities remain or fifth anniversary of Closing Date

27-02-2026

Applied Optoelectronics, Inc. (AAOI) entered into a Texas Net Lease agreement dated February 10, 2026, with Blue Ridge Commerce Center West LLC for 153,928 rentable square feet of premises (Building #3) at Blue Ridge Commerce Center, 16851 Blue Ridge Commerce Dr., Houston, TX, representing 100% of the building and 11.40% of the project. The 130-month lease term commences on or around February 10, 2026, with 5 months of base rent abatement followed by escalating monthly base rent from $66,189 ($0.43/RSF) in months 6-10 to $186,732 ($1.21/RSF) in months 121-130, initial estimated monthly operating expenses of $30,786, prepaid rent of $163,164 applied to month 11, and a $2M security deposit. The premises will be used for general distribution, office, warehouse, and light manufacturing/assembly of PCBs, PCBA, and semiconductors.

• ·Commencement Date: Earlier of Tenant occupancy for business or February 10, 2026
• ·Effective Date: February 10, 2026
• ·Tenant Notice Address (pre-Commencement): 13139 Jess Pirtle, Sugar Land, TX 77478
• ·Landlord Notice Address: c/o George R. Farish II, Trammell Crow Company, 2800 Post Oak Blvd., Suite 400, Houston, TX 77056

27-02-2026

Jewett-Cameron Trading Company Ltd. held its Annual General Meeting on February 27, 2026, where shareholders approved receipt of financial statements for the fiscal year ended August 31, 2025, fixed the board at five directors, elected Charles E. Hopewell, Michelle Walker, Chad Summers, Subriana Pierce, and Ian Wendler as directors, appointed auditors, ratified directors' and officers' acts, and approved executive compensation on an advisory basis. However, several proposals faced significant opposition, including acts and deeds of directors/officers (525,764 shares against out of ~1.66M voted), advisory vote on executive compensation (611,957 against), and transacting other business (666,212 against). All items ultimately passed despite the mixed support.

• ·Item 1 (financial statements and auditor’s report) was duly adopted without specific vote counts provided.
• ·Hopewell received the lowest For votes among directors (1,027,692) and highest withheld (629,290).
• ·Non-votes ranged from 0 to 553,295 across items.

27-02-2026

LightPath Technologies Inc. (LPTH) filed an 8-K on February 27, 2026, including Exhibit 99.1, the February 2026 Investor Day Presentation, under Items 7.01 (Regulation FD Disclosure) and 9.01. The presentation is provided as images with no extractable textual financial data, metrics, or period-over-period comparisons.

27-02-2026

On February 25, 2026, Globe Life Inc.'s Board of Directors expanded from 12 to 14 members and appointed independent directors Derek T. Kan to the Audit Committee and Sandra L. Phillips to the Governance and Nominating Committee, with terms expiring at the April 30, 2026 Annual Meeting of Shareholders. Compensation follows the 2018 Non-Employee Director Compensation Plan, including prorated annual cash retainer of $110,000, equity retainer of $190,000, and $12,500 additional for Mr. Kan's Audit Committee role. There are no arrangements influencing their selection or disclosable transactions under Item 404(a) of Regulation S-K.

• ·Directors determined 'independent' per NYSE rules and Company criteria
• ·No understandings or arrangements pursuant to which Mr. Kan or Ms. Phillips were selected

27-02-2026

InfuSystem Holdings, Inc. (INFU) filed a Form 8-K on February 27, 2026, under Item 7.01 Regulation FD Disclosure, furnishing an Investor Presentation dated February 27, 2026, attached as Exhibit 99.1. The disclosure notes that the information is not deemed 'filed' under Section 18 of the Exchange Act or incorporated by reference into other filings. The filing was signed by Barry Steele, Chief Financial Officer.

27-02-2026

WESCO Distribution, a wholly-owned subsidiary of WESCO International, completed a $1.5B senior notes offering on February 27, 2026, consisting of $650M 5.250% notes due April 15, 2031, and $850M 5.500% notes due April 15, 2034, issued at 100% of principal with net proceeds of approximately $1.48B. The proceeds will be used to redeem all outstanding 7.250% senior notes due 2028 on or after June 15, 2026, and repay a portion of the ABL Facility, effectively refinancing higher-rate debt at lower rates of 5.25-5.50%. No declines or flat metrics reported in this debt issuance event.

• ·Notes accrue interest semi-annually starting October 15, 2026, on April 15 and October 15.
• ·Issuer may redeem 5-Year Notes with make-whole premium prior to April 15, 2028, and up to 35% with equity proceeds; similar terms for 8-Year Notes prior to April 15, 2029.
• ·Change of control requires offer to repurchase at 101% of principal.
• ·Indenture covenants limit liens, restricted payments, sale-leasebacks, and mergers; some terminate upon investment grade ratings.

27-02-2026

Millrose Properties, Inc. (MRP) released its March 2026 investor presentation under Regulation FD, highlighting platform snapshot as of December 31, 2025: 142,139 current homesites across 933 communities in 30 states, $9.2B total land assets, $16.1B total future takedown proceeds, $5.9B shareholders' equity, 9.2% weighted average yield, 26% debt to capitalization ratio, and $1.3B liquidity (including $35M cash and $1.3B revolving credit facility capacity). The presentation emphasizes MRP's homesite option purchase platform, anchored by a relationship with Lennar, with deep sourcing from external manager Kennedy Lewis, and top 10 states accounting for 79.8% of takedown proceeds. No historical comparisons or performance declines are provided.

• ·Top 10 states by takedown proceeds: California (13,345 homesites, $3.4B, 21.1%), Texas (37,548 homesites, $2.9B, 18.2%), Florida (20,526 homesites, $1.9B, 12.1%), with remaining states totaling 29,543 homesites and $3.3B (20.2%)
• ·Management fee fixed at 1.25% on book value of tangible assets

27-02-2026

Chart Industries reported full year 2025 sales of $4.26B, up 2.5% YoY (4.1% excluding non-repeating 2024 items), with orders increasing 13.4% to $5.68B and backlog growing 21.5% to $5.89B. However, Q4 2025 orders declined 23.8% to $1.18B and sales fell 2.5% to $1.08B due to the absence of large prior-year Big LNG orders, while segment performance was mixed with declines in Specialty Products sales (-18.1%) and RSL sales (-5.8%). Adjusted operating margins decreased overall, though some segments like Heat Transfer Systems showed improvement.

• ·Pending acquisition by Baker Hughes at $210 per share, shareholder approval on October 6, 2025, expected close Q2 2026.
• ·Q4 2025 reported diluted EPS $1.01, adjusted $2.51.
• ·Full year 2025 net leverage ratio 2.83.
• ·44% of year-end backlog expected to ship in next 12 months.
• ·Eleventh consecutive quarter with gross profit margin above 30%, seventh above 33%.

27-02-2026

American Integrity Insurance Group reported strong FY2025 results with policies in-force growing 19% YoY to 422K, gross premiums written up 23% YoY to $945M, adjusted net income surging 165% YoY to $105M, and combined ratio improving 17 ppts to 64%; shareholders' equity more than doubled to $337M. However, Q4 2025 showed declines with gross premiums written down 13% YoY to $206M and net premiums earned down 4% YoY to $59M, despite adjusted net income rising 160% to $22M and combined ratio improving sharply to 63%. The company maintained a leading position in Florida residential insurance, ranking #7 in new voluntary policies written (94,988) and #6 in policies in-force (390,751).

• ·Policy retention ratio improved from 75.1% in Q4 2024 to 82.7% in Q4 2025 (+7.6 ppts).
• ·Ranked #6 among all carriers and #3 excluding Citizens/national carriers in new FL voluntary policies written for year ended 12/31/2025.
• ·IPO consummated on May 7, 2025; 10-K for year ended Dec 31, 2025 filed on February 26, 2026.

27-02-2026

iBio, Inc. entered into a new Open Market Sale Agreement (ATM Agreement) with Jefferies LLC on February 27, 2026, enabling at-the-market offerings of up to $100M in common stock pursuant to a new S-3 shelf registration (File No. 333-293864). This follows the termination on February 23, 2026, of a prior ATM Agreement dated July 3, 2024, with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC, which had an aggregate offering limit of $7.35M under S-3 File No. 333-280680. The new facility provides significantly expanded fundraising capacity compared to the prior smaller program.

• ·New ATM sales methods include at-the-market offerings on Nasdaq, block transactions, or privately negotiated transactions.
• ·Jefferies entitled to customary indemnification and no obligation to sell specific volumes.
• ·ATM terminates upon sale of all shares or as permitted by parties.

27-02-2026

Paramount Skydance Corporation (PSKY) will acquire Warner Bros. Discovery, Inc. (WBD) for $31.00 per share in cash, valuing WBD at $81B equity value and $110B enterprise value (7.5x fully synergized 2026 EBITDA), with over $6B in expected synergies from technology, efficiencies, and operations. The deal, unanimously approved by both boards, is funded by $47B in new Class B shares at $16.02/share from the Ellison Family and RedBird Capital Partners, plus $54B debt commitments, and is expected to close in Q3 2026 subject to regulatory and shareholder approvals. Strategic benefits include a combined film library of over 15,000 titles, commitment to 30 theatrical films annually, and enhanced DTC platforms like Paramount+, HBO Max, and Pluto.

• ·Shareholder vote expected in early spring 2026
• ·Conference call and webcast on March 2, 2026 at 8:30am ET
• ·Transaction terminates Paramount's prior all-cash tender offer for WBD
• ·Financial advisors: Centerview Partners LLC, RedBird Advisors (Paramount lead); Allen & Company, J.P. Morgan, Evercore (WBD)

27-02-2026

GoldMining Inc. released audited consolidated financial statements for FY2025 ended November 30, 2025, with total assets increasing 97% to CAD $238M from CAD $121M in FY2024, bolstered by long-term investments rising to CAD $148M (from CAD $39M) and cash growing to CAD $25M (from CAD $12M). However, the company recorded a net loss of CAD $15.3M, improved from CAD $27.3M prior year, while operating loss edged up 3% to CAD $26.3M from CAD $25.6M due to higher general and administrative expenses partially offset by lower exploration costs. Total comprehensive income turned positive at CAD $76M, driven by CAD $104M unrealized gains on long-term investments.

• ·Share-based compensation increased to CAD $3.0M from CAD $2.3M.
• ·Investment in associate fully impaired to $0 from CAD $7.2M.
• ·Deferred tax recovery of CAD $9.8M in FY2025 vs expense of CAD $0.2M in FY2024.
• ·Net loss per share improved to $(0.07) from $(0.13).

27-02-2026

Mechanics Bancorp announced the adoption of Amended and Restated Bylaws effective February 25, 2026, via an 8-K filing on February 27, 2026, covering Items 5.03, 8.01, and 9.01. The bylaws detail governance procedures for shareholder meetings (annual and special, with special meetings callable by the Board, Chair, President, Secretary, or shareholders holding at least 10% of voting shares), board of directors, officers, shares, indemnification, and forum selection. No financial metrics, changes, or impacts are disclosed.

• ·Special meeting requests require a proper form initial request for Requested Record Date, followed by requests from shareholders holding the Requisite Percentage (10%) within 60 days.
• ·Business at special meetings limited to Proposed Business in valid requests, notice, or Board/chair direction.
• ·Detailed shareholder notice requirements under Section 1.12, including questionnaires, representations, and director nominee eligibility.

27-02-2026

Azitra, Inc. (AZTR) filed an 8-K on February 27, 2026, announcing its financial results as of and for the year ended December 31, 2025, via a press release furnished as Exhibit 99.1. The press release details the Company's results of operations and financial condition. No specific financial metrics or period-over-period comparisons are disclosed in the filing itself.

• ·Filing pertains to year ended December 31, 2025.
• ·Securities: Common Stock, par value $0.0001, traded as AZTR on NYSE American.
• ·Company is an emerging growth company.

27-02-2026

Western New England Bancorp, Inc. announced on February 24, 2026, that Paul Picknelly, a member of its Board of Directors, will retire effective May 14, 2026, immediately following the 2026 Annual Meeting of Stockholders. Mr. Picknelly's decision was not due to any disagreement with the company's operations, policies, or practices. No other changes or financial impacts were disclosed.

27-02-2026

Algorhythm Holdings, Inc. entered into an Amended and Restated Employment Agreement with Gary Atkinson as Chief Executive Officer, effective February 23, 2026, for an initial three-year term automatically renewable annually unless 90 days' notice is given. Compensation includes a $360K annual base salary, eligibility for up to 50% ($180K) annual bonus (half guaranteed if employed full year, half tied to capital raise and $10M revenue target for FY2026), and a stock option for approximately 5% of fully diluted common shares vesting quarterly over four years. Additional terms include a change-in-control bonus of up to $540K, standard benefits, and a requirement to spend an average of two days per week in the Fort Lauderdale office.

• ·Stock option exercise price equals closing price of common stock on Nasdaq on Effective Date (February 23, 2026).
• ·Agreement supersedes conflicting terms in 2022 Equity Incentive Plan or stock option grant notice.
• ·Executive permitted to maintain prior consulting arrangement with Stingray Music USA, Inc. approved by Board.
• ·Termination requires 30 days' advance written notice unless for Cause.
• ·Company to register shares underlying stock option via amendment to Form S-8 (File No. 333-268106) or new filing by first anniversary of Effective Date.

27-02-2026

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company, announced an investor conference call on March 4, 2026, at 6:00 a.m. PT / 9:00 a.m. ET to present initial Phase 1 dose-escalation results from the NEO212-01 trial evaluating an oral bioconjugated temozolomide platform for CNS malignancies. The call will cover safety, toxicity, pharmacokinetics, and regulatory next steps, featuring management and Scientific Advisory Board members. No specific data or outcomes were disclosed in this announcement.

• ·Patent protections for NEO™ platform extending to 2038.
• ·NEO100™ and NEO212™ advancing in Phase II trials under FDA Fast-Track and IND status.
• ·Exclusive worldwide license from University of Southern California for NEO100, NEO212, and related patents.
• ·Live webcast accessible at https://www.webcaster5.com/Webcast/Page/3151/53708 or https://investors.neonc.com.

27-02-2026

VisionWave Holdings, Inc. entered into a letter agreement dated February 26, 2026, with YA II PN, Ltd. to issue a $20M promissory note (net of 15% discount) and a warrant for 1,333,333 common shares exercisable for 5 years, under the existing SEPA with $49M remaining commitment after a prior $5M prepaid advance. The funding comes with strict covenants prohibiting related party payments, new indebtedness beyond permitted limits ($250k), variable rate transactions, and liens, while requiring subsidiary guaranties and future registration of warrant shares within 90 days of closing. This provides liquidity but introduces dilution risk and operational restrictions.

• ·SEPA originally dated July 25, 2025, amended January 19, 2025.
• ·Registration Statement for 10.2M SEPA shares declared effective February 17, 2026; no amendment required for new note or warrant shares.
• ·Warrant Registration Statement due within 90 days after Closing Date; demand registration within 45 days of notice.
• ·Prohibitions include prepayments to Evie Autonomous LTD and deferred underwriting commissions from Bannix Acquisition Corp. IPO.

27-02-2026

On February 24, 2026, NextNav Inc.'s Board of Directors increased its size from 9 to 10 members and appointed Lisa Hook as a new director to fill the vacancy, naming her Lead Independent Director and a member of the Technology and National Defense Committee and Compensation and Human Capital Committees. Ms. Hook's compensation includes an initial equity grant of approximately $75,000, an annual equity grant of approximately $175,000, and an annual cash retainer of $80,000, plus standard committee fees. Her term expires at the 2026 Annual Meeting of Stockholders, where she will stand for reelection, and the Company will enter into a standard indemnity agreement with her.

• ·No arrangements or understandings exist between Ms. Hook and any other person regarding her appointment.
• ·No transactions requiring disclosure under Item 404(a) of Regulation S-K involving Ms. Hook.
• ·Indemnity agreement with Ms. Hook to be substantially the same as for other directors (filed as Exhibit 10.2 to 8-K on October 28, 2021).

27-02-2026

Kinetic Seas Inc. (KSEZ) issued a $148,500 promissory note to Labrys Fund II, L.P. on February 23, 2026, for a $135,000 purchase price plus $13,500 OID and prepaid 8% interest of $11,880, maturing in 12 months. The note is convertible into common stock after 180 days at 85% of the lowest closing bid price over the prior 10 trading days, subject to a 4.99% beneficial ownership limit (adjustable to 9.99%). The company must reserve at least 10 million shares for potential conversions, posing dilution risk to existing shareholders.

• ·Default interest accrues at the lesser of 22% per annum or maximum permitted by law on overdue amounts.
• ·Holder may deduct $1,750 from each conversion amount to cover fees.
• ·Conversion rights begin 180 calendar days after Issue Date (approximately August 22, 2026).

27-02-2026

Eastman Kodak Company entered into a new Executive Chairman and CEO Agreement with James V. Continenza, effective January 1, 2026, extending his employment term until December 31, 2030, replacing his prior agreement set to expire February 26, 2027. The agreement includes an annual base salary of $1.2M, annual cash incentive up to 125% of base salary ($1.5M max), a one-time renewal award of 5M RSUs vesting equally over five years starting December 31, 2026, and annual RSU awards valued at $2.5M (half time-vesting over three years, half performance-vesting). Termination provisions provide for two years' salary and incentive, accelerated vesting of certain RSUs, and 18 months of COBRA coverage if terminated without cause or for good reason.

• ·Mr. Continenza must provide 61 days' written notice before exercising certain stock options (February 2019 or July 2020 grants) if post-exercise ownership would exceed 4.99%.
• ·Full Employment Agreement to be filed as exhibit to Form 10-K for year ended December 31, 2025.

27-02-2026

EON Resources Inc. announced on February 24, 2026, that its financial statements for years ended December 31, 2023 and 2024, and quarterly 10-Qs in 2024 and 2025, are no longer reliable due to SEC comments on accounting for non-controlling interest in Class B Equity, prompting a restatement. The restatement will reduce net losses allocated to shareholders from $9.0M to $6.7M in 2023 (allocating $2.3M to NCI) and from $9.1M to $7.5M in 2024 (allocating $1.5M to NCI), while total income/loss, cash flows, and ending shareholder equity of $60.9M as of September 30, 2025 remain unchanged. This non-cash change applies only to historical results, with an immaterial impact on Q1 2025.

• ·Class B Equity issued on November 15, 2023; 75% converted by end of Q3 2024; final conversion in February 2025.
• ·Company will file amended 2024 Form 10-K with restated results; 2025 impacts (immaterial for Q1) in upcoming 2025 10-K.
• ·Restatement discussed by Audit Committee after consultation with independent auditors CBIZ CPAs P.C.

27-02-2026

Healthcare Triangle, Inc. (Nasdaq: HCTI) announced definitive agreements for a registered direct offering of 681,553 shares of common stock (or prefunded warrants) at $5.81 per share, priced at-the-market under Nasdaq rules, expecting gross proceeds of approximately $3.959 million before fees. The closing is anticipated on or about February 27, 2026, with D. Boral Capital, LLC as sole placement agent. No period-over-period comparisons are provided, as this is a one-time financing event involving share dilution.

• ·Shelf registration statement on Form S-3 (File No. 333-276382) declared effective by SEC on January 31, 2024.
• ·Press release dated February 26, 2026; SEC 8-K filing dated February 27, 2026.
• ·Company based in Pleasanton, California.

27-02-2026

On February 25, 2026, CBRE Group, Inc. established new compensation targets for two named executive officers: Chad J. Doellinger (Chief Legal & Administrative Officer and Corporate Secretary) with a $700,000 base salary, $1.15M annual performance award target, and $2.75M total equity award target; and Daniel G. Queenan (Executive Group President, Trammell Crow Company) with a $700,000 base salary, $1.3M annual performance award target, and $3M total equity award target. Compensation targets for other named executive officers Robert E. Sulentic, Emma E. Giamartino, and Vikram Kohli remained unchanged.

• ·Filing submitted by Emma E. Giamartino on February 27, 2026
• ·CBRE Group, Inc. incorporated in Delaware, NYSE: CBRE, principal offices at 2121 North Pearl Street, Suite 300, Dallas, Texas 75201

27-02-2026

IQM Finland Oy and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a SPAC, entered a definitive business combination agreement on February 23, 2026, to take IQM public via American Depositary Shares on a leading U.S. stock exchange, with potential dual listing on Helsinki; the deal aims to fund IQM's advancement toward fault-tolerant quantum computing. IQM, a leader in full-stack superconducting quantum computers with over 300 employees and global presence, and RAAQ will host a conference call/webcast to discuss transaction highlights, with recording available at https://meetiqm.com/investors/. No financial metrics or historical performance data provided; forward-looking statements note significant risks including technical challenges, net losses, and potential redemptions.

• ·Agreement announced February 23, 2026; press release dated February 27, 2026.
• ·IQM headquartered in Finland with presence in France, Germany, Italy, Japan, Poland, Saudi Arabia, Spain, Singapore, South Korea, Taiwan, UK, US.
• ·RAAQ based in Princeton, NJ; IPO prospectus filed April 30, 2025.
• ·Upcoming SEC Form F-4 registration statement including proxy statement/prospectus.

27-02-2026

Data I/O Corporation (DAIO) filed an 8-K on February 27, 2026, under Items 2.02 and 9.01, announcing its fourth quarter 2025 financial results via a press release dated February 26, 2026, furnished as Exhibit 99.0. The filing reports results of operations and financial condition but provides no specific financial metrics in the form itself. Signed by Charles J. DiBona, Vice President and Chief Financial Officer.

• ·Securities registered: Common Stock (DAIO) on NASDAQ
• ·Press release exhibit: Exhibit 99.0 - Data I/O Reports Fourth Quarter 2025 Results

27-02-2026

IP Strategy Holdings, Inc. (IPST) reported preliminary Q4 2025 net revenues of $4.6-4.8M, up ~53-60% QoQ from $3.0M in Q3, and full-year 2025 revenues of $9.8-10.3M, up ~17-23% YoY from $8.4M in 2024, driven by validator operations at >95% gross margins. However, Q4 net loss before taxes swung to $380-384M from Q3 profit of $245.7M, and full-year loss reached $146.5-148.5M from 2024 profit of $0.7M, primarily due to $126.5-129.5M mark-to-market loss on 53.2M $IP Tokens amid a price drop from $8.54 to $1.732. Restructuring closed retail tasting rooms with $3.2-3.6M write-downs but eliminated $19.3M debt (saving >$2M annual interest) and >$5M annual op ex from 2026, net of ~$3.5M revenue loss.

• ·$IP Tokens acquired at average basis of $3.93 per token
• ·Q4 2025 third-party staking fees: 40,595 $IP Tokens
• ·Annual interest expense savings >$2M; op ex savings >$5M from 2026 (net of ~$3.5M revenue loss)

27-02-2026

On February 24, 2026, Ambarella Inc.'s Compensation Committee approved the Fiscal Year 2027 Annual Bonus Plan (FY2027 Bonus Plan), featuring an aggregate target bonus pool approximately 28% larger than the FY2026 plan. CEO Feng-Ming Wang is eligible for a 100% bonus target of his base salary, with other executives (John Young, Chan Lee, John Ju, Yun-Lung Chen) ranging from 40% to 75%; payouts are weighted 1/3 each on revenue, operating profit, and non-financial objectives, with a maximum of 167% of target. No threshold performance results in zero funding, and payouts require continued employment.

• ·Compensation Committee and Board have discretion to adjust bonus pool size and individual payouts.
• ·Payouts to be made no later than two and one-half months after end of FY2027.
• ·Performance between threshold and target uses linear interpolation.

27-02-2026

Landmark Bancorp, Inc. selected Forvis Mazars, LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2026, following a competitive process by the Audit Committee, with Crowe LLP dismissed effective after completing the 2025 audits. There were no disagreements or reportable events with Crowe during fiscal years 2024 and 2025, and Crowe's audit reports were unqualified. Crowe provided a letter dated February 27, 2026, concurring with the disclosures.

• ·Crowe’s audit reports on consolidated financial statements for fiscal years ended December 31, 2024 and 2025 did not contain adverse opinions, disclaimers, or qualifications as to uncertainty, audit scope, or accounting principles.
• ·No prior consultations with Forvis Mazars on accounting principles, audit opinions, or related matters before retention.
• ·Forvis Mazars engagement begins with review of Q1 2026 quarterly consolidated financial statements, subject to client acceptance procedures.

27-02-2026

Nuburu, Inc. amended its Amended and Restated Certificate of Incorporation to implement a reverse stock split, converting every 4.99 shares of Common Stock into one share, effective at 5:00 p.m. Eastern Time on February 27, 2026. The amendment, approved by the board of directors and stockholders, includes no changes to the number of authorized shares and rounds up fractional shares to full shares. This corporate action was filed with the Delaware Secretary of State on February 25, 2026.

• ·Filed with Delaware Division of Corporations at 05:00 PM on February 25, 2026 (SR 20260824506, File Number 7992745)
• ·No fractional shares issued; rounded up to full share

27-02-2026

Flagstar Bank, N.A. (NYSE: FLG) announced its 2026 Annual Meeting of Shareholders on June 9, 2026, at 10:00 a.m. ET in a virtual format, with a record date of April 10, 2026; proxy materials will be filed with the OCC and SEC. As of December 31, 2025, the Bank reported $87.5B in assets, $61.0B in loans, $66.0B in deposits, and $8.1B in stockholders' equity, while operating approximately 340 locations across ten states. The release includes cautionary forward-looking statements referencing prior events like the October 2025 reorganization and no new performance metrics.

• ·Bank headquartered at 102 Duffy Avenue, Hicksville, NY 11801.
• ·Operates with strong footholds in greater New York/New Jersey, upper Midwest, Florida, and West Coast.

27-02-2026

Trump Media & Technology Group (TMTG) reported full-year 2025 results with financial assets more than tripling YoY to $2.5B from $776.8M at end-2024 and positive operating cash flow of $14.8M versus a $61M outflow in 2024, bolstered by $44M in cash proceeds from a bitcoin options strategy. However, revenue was only $3.7M while consolidated net loss reached $712.3M, primarily from non-cash digital asset impairments. The filing also references a proposed merger with TAE Technologies.

• ·Non-cash losses from fair value changes in digital assets and pledged digital assets: $403.2M
• ·Non-cash losses from fair value mark-to-market of digital asset related securities: $178.8M
• ·Non-cash stock-based compensation: $59.2M
• ·Non-cash interest expense on debt: $27.0M
• ·Positive operating cash flow in each of the last three quarters of 2025

27-02-2026

lululemon athletica inc. responded to Chip Wilson’s press release regarding his nomination of three director candidates for election at the 2026 Annual Meeting of Shareholders, stating it has engaged in good faith through numerous meetings but disagrees with Wilson’s characterization of interactions. The Board requested interviews with the nominees, but Wilson conditioned access on full settlement terms, allowing only preliminary conversations with one nominee, Marc Maurer. The company remains open to constructive dialogue with Wilson and other shareholders in their best interests.

• ·Company intends to file definitive proxy statement on Schedule 14A and white proxy card with SEC for 2026 annual meeting.
• ·Previous proxy statement filed April 29, 2025; recent Form 4 filings on June 11-13, 2025, December 17-29, 2025, and January 2, 2026.
• ·Investor contacts: Howard Tubin (604-732-6124); Media: Madi Wallace (604-732-6124).

27-02-2026

Odyssey Marine Exploration Inc. entered into an Amended and Restated Joint Venture Agreement dated February 27, 2026, with Capital Latinoamericano (CapLat) and affiliates including Oceanica Resources, Oceánica Resources México (ORM), Phosagmex (JV entity), and Exploraciones Oceánicas (ExO) to advance a fertilizer production project extracting phosphate ore from Mexico's EEZ in the Gulf of Ulloa. The agreement amends the original December 23, 2024 JV agreement (amended June 5, 2025) and highlights progress such as JV entity formation, initial contributions, court-ordered reinstatement of mining concessions, exclusivity agreements with dredging and processing providers, substantial completion of the MIA application, and development of business plans. No financial metrics or declines reported.

• ·Concessions: 'Don Diego Reducción' (244813/240744), 'Don Diego Norte' (242994), 'Don Diego Sur' (242995)
• ·Original JV Agreement: December 23, 2024 (amended June 5, 2025)
• ·Assignment Agreement between ExO and Phosagmex: June 5, 2025
• ·Tax Assessment: Ruling Letter 500-36-07-03-01-2022-10636 dated September 8, 2022

27-02-2026

Pinnacle West Capital Corp (PNW) and APS presented an investor deck highlighting robust Arizona economic growth driving 2.0% residential sales growth and 7.5% C&I sales growth in 2025, with long-term weather-normalized retail sales growth guidance raised to 5%-7% through 2030 and EPS growth of 5%-7% CAGR off 2024 midpoint. Rate base is projected to grow from $12.23B in 2024 to $15.7B in 2028 (ACC), supported by a $10.35B capital plan through 2028 focused on generation, transmission, and distribution investments including up to 2GW new gas capacity. While C&I and overall sales show strong momentum with 9 consecutive quarters of 4%-6.8% weather-normalized growth, residential customer growth remains moderate at 1.5%-2.5% through 2026E.

• ·9 consecutive quarters of weather-normalized retail sales growth within or exceeding 4%-6% long-term guidance through Q3 2025.
• ·2026 sales growth guidance 4%-6%; residential customer growth guidance 1.5%-2.5%.
• ·APS equity layer: 51.93% (ACC effective 3/8/2024), 52.28% (FERC 6/1/2025); Allowed ROE 9.55% ACC, 10.75% FERC.
• ·2026 financing: ~$3.8B cash ops, $2.6B-$2.9B APS debt, $300M-$350M PNW debt, $1.0B-$1.2B PNW equity (75% priced).

27-02-2026

OpGen, Inc. (OTC: OPGN) announced its name change to CapForce Inc., effective February 27, 2026, to reflect a repositioning toward digital investment banking and fintech services targeting high-growth mid-sized companies with $1B-$10B market caps. The company plans to change its ticker to 'CFOR' and is developing a digital platform with AI-powered robo-advisory and cap table management, subject to market and regulatory factors; its controlling shareholder AEI Capital Group manages over $7B in AUM. Forward-looking statements highlight risks including rebranding costs, execution challenges, and potential customer/investor confusion.

• ·Name change effective February 27, 2026
• ·Expected ticker symbol change to 'CFOR'
• ·Subsidiaries: CapForce International Holdings Ltd. and iCapX Sdn. Bhd.
• ·AEI Capital Group footprints: Hong Kong, Kuala Lumpur, Singapore, London, Washington D.C.

27-02-2026

On February 27, 2026, Bridgewater Bancshares, Inc. and its subsidiary Bridgewater Bank entered into an Equity Distribution Agreement with Piper Sandler & Co. to issue and sell up to $50 million of common stock through at-the-market offerings. The agreement allows sales via various methods, with the company paying a 2.5% commission on gross sales prices; there is no obligation to sell any shares, and either party may terminate at any time. Net proceeds, if any, will support general corporate purposes such as subsidiary investments, working capital, capital expenditures, stock repurchases, debt repayment, or acquisitions.

• ·Sales under the agreement will be made pursuant to shelf registration statement Form S-3 (No. 333-284662), effective February 10, 2025, with prospectus supplement filed February 27, 2026.
• ·Agreement includes customary representations, warranties, covenants, indemnification, and expense reimbursements.

27-02-2026

Pulse Biosciences, Inc. announced the immediate resignation of Kevin P. Danahy, its Chief Commercial Officer, effective February 27, 2026. The departure was not due to any disagreement with the company's operations, policies, practices, or accounting matters. The company recognized Mr. Danahy's contributions to senior management and early commercialization efforts.

• ·Resignation effective immediately
• ·No disagreement on operations, policies, practices, or accounting
• ·Company headquartered at 601 Brickell Key Drive, Suite 1080, Miami, Florida 33131

27-02-2026

Lyra Therapeutics, Inc. received a notice of default on February 23, 2026, from RVAC Medicines (US), Inc. for failing to pay $484,431.92 in rent under a sublease for office space in Waltham, MA, comprising two invoices of $242,215.96 each due February 1 and March 1, 2026. This follows the company's January 12, 2026 announcement of ceasing operations and initiating a wind-down while pursuing strategic options, with failed negotiations to terminate the sublease by January 31, 2026. The company is evaluating options to resolve obligations outside bankruptcy, but no assurance of success is provided.

• ·Sublease agreement dated December 21, 2023 for premises at 880 Winter Street, Suite 1002, Waltham, MA 02451
• ·Principal executive offices at 480 Arsenal Way, Watertown, Massachusetts 02472

27-02-2026

American Healthcare REIT, Inc. entered into a new ATM Equity Offering Sales Agreement on February 27, 2026, for the offer and sale of up to $1.75B in common stock through multiple agents, terminating a prior ATM program from August 8, 2025, under which $230.1M remained unsold. Proceeds, if any, will be contributed to the Operating Partnership for general corporate purposes including debt repayment and investments. Sales depend on market conditions and company determinations, with agent commissions not exceeding 2.0%.

• ·Sales Agreement includes provisions for forward sale agreements with Forward Purchasers, allowing physical, cash, or net share settlement.
• ·Prospectus supplement dated February 27, 2026, under shelf registration Form S-3 (No. 333-281488) filed August 12, 2024.
• ·Legal opinion provided by Venable LLP (Exhibit 5.1).

27-02-2026

On February 27, 2026, IonQ, Inc. filed a prospectus supplement to its Form S-3ASR registration statement (File No. 333-285279, originally filed February 26, 2025), covering the resale by certain selling stockholders of an aggregate 5,127,459 shares of common stock (par value $0.0001 per share). The filing includes a legal opinion from Paul, Weiss, Rifkind, Wharton & Garrison LLP as Exhibit 5.1. No financial performance metrics or period comparisons are disclosed.

• ·Prospectus supplement filed with reference to Registration Statement File No. 333-285279.
• ·Securities registered on New York Stock Exchange.

27-02-2026

TRG Latin America Acquisitions Corp., a blank check company, priced its initial public offering of 20,000,000 units at $10.00 per unit, raising $200M, with units listing on Nasdaq under 'TRGSU' starting February 26, 2026. Santander serves as sole book-running manager and has a 45-day option to purchase up to 3,000,000 additional units for over-allotments. The offering is expected to close on February 27, 2026, subject to customary conditions.

• ·Units consist of one Class A ordinary share and one right for one-tenth of a Class A ordinary share upon business combination.
• ·Class A shares and rights to trade separately under 'TRGS' and 'TRGSR' no later than 52nd day after February 25, 2026.
• ·Registration statement effective February 25, 2026.
• ·Company is Cayman Islands exempted entity targeting business combinations, focusing on Latin America expertise.